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I. General introduction 
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Hepatocytes, parenchymal cells of the liver, perform important functions such as metabolism, 
detoxification, and protein synthesis for supporting homeostasis of the body. Hence, human hepatocytes are 
essential materials for research of drug discovery. However, it is limited to obtain human hepatocytes from 
liver of brain-dead donors or normal part of tissues excised by surgery, because donors as source of supply 
are shortage. Furthermore, most of hepatocytes are not able to proliferate and lose metabolic functions in 
vitro. These problems are a bottleneck in research of drug discovery. This study aims to establish a method 
for obtaining a large number of functional human hepatocytes having drug metabolizing activities for long 
term in vitro.  
Generally isolated hepatocytes cannot be maintained as replicating differentiated cells in vitro. In the 
previous study, we reported that small sized hepatocytes isolated from rat or h-livers showed highly 
proliferative ability under an appropriate culture condition [1-4]. Therefore, in Chapter II, I tried to develop 
a method for propagating h-hepatocytes in vitro. As a result, I demonstrated the presence of colony forming 
parenchymal hepatocytes (CF-PHs) in humans and characterize them with respect to growth and 
differentiation potential. In this study, I established a method of propagating primary h-hepatocytes in vitro. 
However, I considered that it is difficult to obtain large amount of differentiated h-hepatocytes using this 
method, because ratio of CF-PHs was very low (~0.1%) in h-hepatocytes.  
In the previous study, our group tried to propagate h-hepatocytes in mouse liver (in vivo) in order to 
obtain them more efficiently than in vitro procedure. As a result, we succeeded in producing a chimeric 
mouse (PXB-mouse) in which 70% or more of the liver was replaced with human hepatocytes by 
transplanting ch-hepatocytes into the liver of urokinase-type plasminogen activator (uPA)/severe combined 
immunodeficient (SCID) mice or cDNA-uPA/SCID mice [5, 6]. PXB-mice are considered a useful animal 
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model for predicting h-drug metabolism, toxicity and efficacy. Transplanted h-hepatocytes were able to 
proliferate 500 to 1000 times in the host mouse liver. We were able to obtain large amount of fresh 
h-hepatocytes from PXB-mice (PXB-cells) by a collagenase perfusion method. 
In Chapter III (1) and III-(2), I determined whether the PXB-mouse could serve as a novel source of 
fresh h-hepatocytes for in vitro drug development studies.  
In Chapter III-(1), PXB-cells were isolated from PXB-mice, and cytochrome P450 (CYP) 1A2, 2C9, 
2C19, 2D6, 2E1, 3A and UDP-glucuronosyltransferase (UGT) activities of PXB-cells were determined and 
compared with ch-hepatocytes. Effects of cryopreservation of PXB-cells on CYP and UGT activities were 
also analyzed.  
Recently, we demonstrated that cultured PXB-cells were susceptible to HBV infection and that 
HBV-infected PXB-cells can be maintained for more than 3 weeks when the PXB-cells were cultured on 
collagen-coated dishes at a high density (2.13 ×105cells/cm2) [7]. Therefore, PXB-cells have been used for 
in vitro efficacy studies of anti-HBV agents [7]. In those studies, we found that PXB-cells can attach to 
collagen-coated dishes in high density cultures without the detachment seen in rodent hepatocytes and can 
be maintained for more than 3 weeks [7].  
In Chapter III-(2), we determined CYP, UGT, transporter mRNA expression and the activities of CYP3A 
and multidrug resistance-associated protein (MRP2) transporter and bile salt export pump (BSEP) in the 
high density 2D-cultures of PXB-cells for 21 days. I also evaluated differences in donors and individual 
PXB-mice using ch-hepatocytes isolated from three different donors. Finally, the role of the high density 
culture condition was determined by microarray analysis of PXB-cells cultured at high and low density. 
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II. Growth and differentiation of colony-forming human hepatocytes in vitro
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Abstract
Background/Aims: Parenchymal hepatocytes (PHs) of rat contain colony-forming parenchymal hepatocytes 
(CF-PHs) as a small fraction. We aimed to demonstrate the presence of CF-PHs in humans and characterize 
them with respect to growth and differentiation potential. 
Methods: Human PHs were co-cultured with Swiss 3T3 cells in the medium containing human serum, 
EGF, nicontinamide, and ascorbic acid 2- phosphate. To examine differentiation potential hepatocytes were 
cultured on gels of Matrigel Matrix. 
Results: Few PHs formed colonies, the colony-forming efficiency being as low as 0.01-0.09%. The 
CF-PHs could be subcultured up to 7 passages. They showed a liver epithelial cell-like morphology, and 
immunocytochemically positive for albumin (ALB), cytokeratin (CK) 7, 8, 18, and 19 in a pre- and early 
phase-confluence, whereas they showed a typical differentiated hepatocyte-like morphology, and positive 
1-antitrypsin, but negative for CK7 and 19 in condensed regions at confluence. The CF-PHs at late 
confluence expressed mRNAs of ALB, HNF4, and isoforms of cytochrome P450 at low levels. However, 
when cultured on Matrigel, these cells expressed them at high levels comparable to those of original PHs.  
Conclusions: We concluded that the human liver contains highly replicative hepatic progenitor-like 
cells as a minute population that retain a normal differentiation potential. 
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Introduction
 Generally, hepatocytes in vitro can be maintained as replicating differentiated cells for a limited period. 
We devised a culture medium, hepatocyte clonal growth medium (HCGM), that supports the growth of rat 
hepatocytes for a longer period [1-3]. Using HCGM we were able to demonstrate the presence of the 
colony-forming parenchymal hepatocytes (CF-PHs) as small hepatocytes (SHs) that have a much higher 
growth potential than conventional PHs [3]. We also showed the presence of replicative human SHs that 
continue to increase the colony size up to around 35 days when cultured in modified HCGM containing 
human serum (HS) and Swiss 3T3 cell-conditioned medium (3T3-CM) [4]. However, CF-PHs have not 
been isolated as a pure fraction and, thus, not been characterized well yet.  
   The present study was performed, firstly, to determine the occupancy of CF-PHs in the human liver, 
secondly, to propagate them by serial subculture, and, thirdly, to characterize them in terms of 
differentiation potential. As a result, we demonstrated the presence of CF-PHs in human PHs and were able 
to obtain a pure fraction of CF-PHs by serial subcultivation. CF-PHs were characterized in terms of growth 
potential and differentiation capacity. 
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Materials and methods
Isolation, cryopreservation, and thawing of human hepatocytes
   The present study was performed under the ethical approval of the Hiroshima Prefectural Institute of 
Industrial Science and Technology Ethics Board. Liver tissues were obtained from 15 donors (Table 1) in 
hospitals after receiving their consent before operations according to the 1975 Helsinki declaration.  
   Hepatocytes were isolated as previously [4] with some modifications. Previously we isolated a 
SH-containing NPC fraction as the centrifugal supernatant at 50 x g for 1 min [4]. In the present study we 
isolated PHs as the pellets at 50 x g for 2 min, because their colony-forming efficiency (0.063%) was much 
higher than that (0.013%) at 50 x g for I min. Some of the isolated PHs were cryopreserved and thawed as 
previously [5]. These cryopreserved and thawed (C-T) PHs were dubbed C-T PHs. The viability of cells 
was determined by the trypan blue exclusion test. Cells were counted with a hemocytometer. We also used 
cryopreserved human hepatocytes from a 9-month-old Caucasian boy (IVT079) provided by In vitro
Technologies Inc.(Baltimore, MD). The hepatocytes were thawed as described above. These hepatocytes 
were called C-T 9MM.  
Culture of PHs
   PHs were inoculated at 8 x 103 cells/cm2 in 35-mm dishes (Becton Dickinson Labware, Franklin, NJ) 
containing 1.8 ml of h-HCGM for cultures and on Sumilon Celldesks (Sumitomo Bakelite, Tokyo, Japan) 
in 24-well plates (Becton Dickinson Labware) containing 0.4 ml of h-HCGM for immunocytochemical 
examinations except that PHs isolated from donor No. 16F1 were inoculated at 4 x 103 cells/cm2 in dishes 
and Celldesks. The ingredients and their concentrations of h-HCGM were identical to the previously 
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reported HCGM [4] except that 3T3-CM and dimethyl sulfoxide (DMSO) were not incorporated. The cells 
2-incubator. Swiss 3T3 cells (American Type Culture Collection, 
Rockville, MD) were treated with mitomycin C [6] and were added at 4 x 103 cells /cm2 to the cultures at 
the next day after the start of culture and every 10 days during culture. h-HCGM was refilled twice per 
week during culture. 
   PHs in primary culture grew and became confluent in 35-mm dishes around 30 days after plating. For 
serial subculturing, the cells were detached by treating with 0.25% trypsin and 1 mM EDTA, and 
inoculated at 4 x 103 cells/cm2 in new 35-mm dishes. Swiss 3T3 cells were incorporated into the dishes as 
above.  
   The concentration of albumin (ALB) in culture media was determined with Human ALB ELISA 
Quantitation Kit (Bethyl laboratories Inc., Montgomery, TX). Cellular proteins were quantified with Protein 
Assay Kit (Bio-Rad, Hercules, CA) as previously [7]. 
Determination of colony-forming efficiency of PHs
   PHs were cultured on Celldesks, fixed in - -cytokeratin 
(CK) 18 mouse monoclonal antibodies (Amersham Pharmacia Biotech, Piscateway, NJ). Hepatocyte 
colonies were counted as clusters containing more than 8 CK18-positive (CK18+) cells, and the 
colony-forming efficiency was calculated by dividing the number of colonies by the number of inoculated 
PHs. 
Immunocytochemistry
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Cells were fixed in ethanol at -
against human ALB (Dakopatts, Glostrup, Denmark), human a1-antitrypsin ( 1-AT, Dakopatts), human 
1-fetoprotein (AFP, Dakopatts), and mouse monoclonal antibodies against CK8 (Amersham Pharmacia 
Biotech), CK18, CK7, and CK19 (Progen Biotechnik GmbH, Bretonneux, France). Antibodies were 
visualized as previously [2].  
Culture of cells in spheroids
   Matrigel Matrix solution (BD Biosciences, Bedford, MA) was dissolved in DMEM at 5 mg/ml, 2 ml of 
which was added into each well of 6- min. CF-PHs 
from donor No. 12M (12M-CF-PHs) at 3 passages in subculture or HepG2 cells were inoculated at 105
cells/cm2 -HCGM. At 24 h after plating 
the media were changed to d-HCGM prepared by adding DMSO at 1% to h-HCGM, and removing 
nicotinamide and HS from it. The d-HCGM was refilled every 3 days during culture. Spheroids were 
recovered with BD Cell Recovery Solution (BD Biosciences).  
Quantification of mRNAs 
We examined whether C-T procedures had caused breaks in RNA of PHs. Total RNAs were extracted 
from fresh and C-T PHs of 3 donors, 51M, 53M2, and 68F, and electrophoresed on agarose gels. There 
were no significant differences in the banding patterns of 28S and 18S RNA between fresh and the 
corresponding C-T PHs, which indicated that the C-T procedure did not cause such breaks.  
   12M-CF-PHs at 3 passages in subculture were divided into two groups. One group was cultured in 
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dishes as monolayers and the other group was cultured on Matrigel as spheroids. HepG2 cells were 
similarly treated. Total RNAs were obtained from these 4 different cell preparations. cDNAs were 
synthesized using 1 µg of total RNA, PowerScript RT (Clontech labolatories, Inc., Palo Alto, CA) and 
Oligo(dT)12-
were measured by real-time quantitative RT-PCR using the previous primers [5] except those for AFP 
- - CAGCTTGTGACAGGTTCTGGA) and a 
SYBR Green dye [8]. Copy numbers of mRNA in the cDNA samples were calculated as previously [8]. 
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Results
Growth and morphology
   C-T 9MM-PHs were thawed, seeded on dishes, and co-cultured with Swiss 3T3 cells up to 20 days (Fig. 
1A-H). Some of the attached hepatocytes were marked and monitored for their growth during the culture. A 
small number of single cells started to divide at 5 days, grew slowly but steadily, and formed colonies. 
Similarly, freshly isolated 16F2-PHs were cultured up to 33 days for the observation of cell morphology 
(Fig. 1I and J). The cells showed a liver epithelial cell-like (flat and spread) morphology at 20 days when 
they were in a growing phase (Fig. 1I). They grew to confluence at 33 days after plating (Fig. 1J). The cells 
in condensed regions showed a typical hepatocyte-like (cuboidal and densely packed) morphology. PHs 
were obtained from 11 donors whose age ranged from 3 to 72 years and cultured for 20 days. The 
colony-forming efficiency was variable from 0.01% to 0.09%, but the efficiency significantly decreased as 
donors aged (Fig. 2A). 
Growth of CF-PHs in subculture 
PHs from both younger donors, 3M, 12M, 16F2, and older ones, 63M and 72M1, grew under serial 
subculture (Fig. 2B). Population doubling time (PDT) at passage 4 of older hepatocytes were larger than 
that of younger ones. The possible maximum passage number of CF-PHs of younger and older donors was 
7 and 5, respectively. These results indicated that the growth potential of CF-PHs is correlated with the age 
of donor. 
Phenotypes of CF-PHs in subculture 
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The expression of liver-specific marker proteins was determined during subculture of 3M- and 
12M-CF-PHs. There were no noticeable differences in their expression profiles between 3M- and 
12M-CF-PHs. 3M-CF-PHs at 2 passages were cultured up to 13 days when they were still in a 
pre-confluence or an early phase of confluence. These cells were CK8+ (Fig. 3A) and CK18+ (data not 
shown), markers of both hepatocytes and bile duct cells, and CK7+ (data not shown) and CK19+ (Fig. 3B), 
markers of bile duct cells. 12M-CF-PHs at 3 passages were further cultured up to 27 days when they 
became confluent. They were ALB+ (Fig. 3C), a universal hepatocytic marker. Especially, CF-PHs in 
condensed regions were heavily ALB+. CF-PHs expressed 1-AT, a marker of mature hepatocytes, in 
condensed regions, but not in non-condensed regions (Fig. 3D). These cells were AFP- (Fig. 3E), a marker 
of immature or neoplastic hepatocytes. The CF-PHs were also subjected to double immuno-staining for 
a1-AT and CK19 (Fig. 3G, H, and I). CF-PHs in condensed regions were strongly 1-AT+ (Fig. 3G and I), 
but CK19- (Fig. 3H and I). Double immuno-staining of 1-AT and CK7 showed that the CK7 expression 
pattern was identical to that of CK19 (data not shown).  
Phenotypes of CF-PHs in spheroids
12M-CF-PHs at 3 passages were detached from dishes, and inoculated in dishes (Fig. 4A) or on 
Matrigel (Fig. 4C), and cultured for 7 days. Similarly, HepG2 cells were cultured as a reference cell (Fig. 
4B and D). Both types of cells became confluent at 7 days in dishes (Fig. 4A and B). On Matrigel, both 
12M-CF-PHs and HepG2 cells aggregated at 1 day and formed spheroids with diameter of approximately 
100 µm at 7 days (Fig. 4C and D). CF-PHs of other donors such as 16F2 were also able to form spheroids. 
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12M-CF-PHs in spheroids were subjected to double immuno-staining for ALB and CK7 (or CK19). 
They were both ALB+ and CK7+ (also CK19+) (data not shown). ALB secretion was quantified during 
culture (Fig. 5). The secretion level from 4 to 7 days increased 2.6-fold in monolayers as compared to that 
from 1 to 4 days, whereas the level increased 6.6-fold in spheroids.  
   The above results suggested that spheroid-culture induces CF-PHs to express differentiated phenotypes. 
To further demonstrate such effects of spheroid-culture, the expression level of mRNAs of 
hepatocyte-differentiation marker proteins were compared between monolayer- and spheroid-cultures. This 
comparative study was performed using C-T PHs. Thus, before such experiments, gene expression profiles 
of C-T PHs was investigated in relation to those of fresh PHs. Total RNAs were extracted from C-T and 
fresh PHs of 3 donors, and used for quantifying mRNA of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ALB, HNF4, and cytochrome P450 isozymes (CYPs) (Fig. 6A). mRNAs of GAPDH, CYP2C9, 
and CYP2C19 in C-T PHs were expressed at a similar level as in fresh PHs. The expression of CYP2D6 
and CYP3A4 in C-T PHs was higher than in fresh ones, whereas that of ALB, HNF4, CYP1A1, and 
CYP1A2 was lower in C-T PHs. 
C-T PHs were prepared from 12M. Aliquots of them were used for total RNA extraction and the 
remaining was subcultured to 3 passages. CF-PHs at 3 passages and HepG2 cells as a reference cell were 
cultured in monolayers and spheroids for 7 days, and used for total RNA extraction. These RNAs were used 
to measure mRNAs of GAPDH, ALB, HNF4, AFP, and CYPs by real-time RT-PCR. The expression level 
of GAPDH mRNA was similar among monolayer- and spheroid-cultures of both CF-PHs and HepG2 cells, 
which was higher than that of the original (C-T PHs) level (Fig.6B). CF-PHs in monolayer expressed 
mRNAs of ALB (Fig. 6C) and HNF4 (Fig. 6D) at low levels as compared to the original level. In contrast, 
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their expressions were significantly elevated to levels comparable to the original C-
cultured in spheroids. CF-PHs in both of monolayer-and spheroid-culture did not express AFP mRNA as in 
the case of C-T PHs (Fig. 6E). HepG2 expressed AFP mRNA at a high level. The original C-T PHs variably 
expressed mRNAs of CYPs (1A1, 1A2, 2C9, 2C19, 2D6, and 3A4) as shown in Fig. 6F. CF-PHs expressed 
them at very low levels in monolayer- culture. It was noteworthy that CF-PHs gained a mRNA expression 
profile of CYPs similar to that of the original C-T PHs in spheroid-culture. Such effects of spheroid-culture 
were not observed on HepG2 cells. They expressed mRNAs of ALB (Fig. 6C), HNF4 (Fig. 6D) and AFP 
(Fig. 6E) at a high level and expressed mRNAs of CYPs at an extremely low level (Fig. 6F) in both types 
of culture.  
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Discussion
Previously, we cultured a human nonparenchymal cell (NPC) fraction in medium containing 3T3-CM, 
and showed that CF-PHs present in the NPC fraction can grow well [4]. In the present study we made 
primary cultures of human PHs in the presence of Swiss 3T3 cells and demonstrated the presence of 
CF-PHs, their occupancy rate being quite low. We were able to propagate them by serial subculturing.  
In primary cultures of human PHs, we observed a small number of single cells started to divide at 5 
days, grew slowly but steadily, and formed colonies. Such CF-PHs were characterized by phenotyping at 
earlier time points of culture. Most of the hepatocytes were immunocytochemically ALB+ and CK19-. The 
primary hepatocyte population contained ALB+ and CK19+ cells at an occupancy rate of ~0.02%. The ratio 
of the number of colonies with ALB+ and CK19+ cells, and ALB- and CK19+ to that of total colonies at 4 
days of primary culture was 80 and 20%, respectively. The cells in all the colonies observed so far at 7 and 
21 days in primary culture were ALB- and CK19+, strongly suggesting that originally ALB+ and CK19- cells 
became ALB- and CK19+ in the currently adopted culture conditions. Therefore, it is most likely that the 
biliary/progenitor cell features of CF-PHs are acquired during the periods of subculture. However, the 
possibility that ALB+ and CK19+ cells present at an occupancy rate of ~0.02% at the start expanded during 
culture can not be completely excluded at present.  
   Human CF-PHs were able to be subcultured within limited passages. CF-PHs from young donors could 
be passaged 7 times, PDT at passage 4 being170-220 h, and, then the cells became senescent. CF-PHs from 
older donors were passaged only 5 times at most. They grew more slowly, their PDT at passage 4 being 
650-1200 h. These results suggested that replication potential of human CF-PHs is correlated with the age 
of donors. It should be emphasized that the cumulative population doubling level (CPDL) of CF-PHs from 
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younger donors, 3M and 12M, were as high as 19.3 and 24.7 during 300 days, respectively. 
Gibson- -15 times [9], using as medium supplemented 
with insulin, transferrin, hydrocortisone, EGF, and FBS. FBS was prescreened for their subculture, which 
was said to be important to obtain an optimal growth of the cells. Only 2 of the tested 7 FBS lots supported 
the growth of normal human PHs. PDT of PHs during subcultures was calculated as ~64 h. These PHs 
expressed ALB and CK18, but not AFP. At present, it is unclear whether these proliferative hepatocytes are 
identical to the CF-PHs characterized in the present study. CF-PHs showed a liver epithelial cell-like 
morphology when they were in the growth phase and in an early phase of confluence, whereas they showed 
a typical hepatocyte-like morphology in condensed regions at confluence. CF-PHs expressed ALB, and 
CK7, 19, 8, and 18, but not 1-AT in the former conditions, indicating that these cells are able to express 
traits of both hepatocytes and biliary cells. In accordance with the morphological characteristics, CF-PHs in 
the condensed region expressed hepatocytic traits such as ALB, CK8 and 18, and a1-AT, but not biliary 
traits such as CK7 and 19. Thus, the CF-PHs seem to be hepatic progenitor-like cells existing even in the 
adult liver. 
   Previously, we devised HCGM as a culture medium that supports the growth of rat PHs [1]. Rat PHs 
grew in HCGM when co-cultured with NPCs [2] or Swiss 3T3 cells [6]. The growth promoting activity of 
3T3 cells was partly replaceable with 3T3-CM. The active principles in 3T3-CM were HGF and 
pleiotrophin [6, 8]. In the present study we showed that 3T3-CM also supported the growth of human PHs, 
although its activity was less than that of 3T3 cells (data not shown).  
   A putative adult rat hepatocyte progenitor cells, Lig-8, elevated the expression of proteins of C/EBP , 
ALB, and CYPs when cultured in spheroids [10]. We examined whether human CF-PHs in spheroid culture 
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elevate differentiation-related genes. The mRNA expression level of ALB, HNF4, and CYPs of CF-PHs 
were low in monolayer-culture. However, when these CF-PHs were cultured in spheroid, they regained the 
expression of mRNAs of ALB and HNF4 to a level comparable to that of the original PHs, i.e., the cells 
before cultivation, and also regained a mRNA expression profile of CYPs of 2C9, 2C19, and 3A4 similar to 
that of original PHs. On the other hand, HepG2 cells expressed mRNAs of ALB and HNF4 even in 
monolayers to levels higher than those of PHs or cultured CF-PHs. In spite of such a high expression of 
HNF4 mRNA, HepG2 cells did not express CYP mRNAs in both monolayer- and spheroid-culture. Using 
an adenovirus-mediated antisense targeting method, a research group showed that the expression of CYPs 
in human PHs is regulated by HNF4 [11]. Currently, we suppose that human CF-PHs cultured in spheroids 
reexpress hepatocyte specific differentiation markers through the up-regulation of HNF4 expression. 
   In summary, the present study demonstrated the presence of CF-PHs, a highly replicative compartment 
of human PHs, even in the adult human liver. These CF-PHs can be serially subcultured, retaining their 
normal hepatocytic characteristics. These cultures should be useful to study the cellular and molecular 
mechanisms of growth, differentiation, toxicity, metabolism, and carcinogenesis of human hepatocytes. 
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Table and figures
Table 1
Sources of liver tissues
 Donor Age  Sex  Disease of excised tissues Wet weight  Viability 
 No.     (g) (%) 
 3M 3 male Neuroblastoma  3.4  93.9 
 12M 12 male Hepatocellular carcinoma 7.9 91.5 
 16F1 16 female Focal nodular hyperplasia 40.4 88.5 
 16F2 16 female OTC* deficiency 32.5 94.5 
 45F 45 female Metastatic liver tumor 27.4 75.8 
 51M 51 male Metastatic liver tumor 29.5 89.5 
 53M 53 male Metastatic liver tumor 10.6 91.6 
 53M2 53 male Metastatic liver tumor 16.4 93.8 
 58F 58 female Cholangioma 6.4 95.5 
 61F 61 female Metastatic liver tumor 4.4 80.4 
 63F 63 female Metastatic liver tumor 15.7 89.3 
 63M 63 male Metastatic liver tumor 5.4 87.3 
 68F 68 female Metastatic liver tumor 27.2 92.2 
 72M1 72 male Metastatic liver tumor 14.4 40.0 
 72M2 72 male Metastatic liver tumor 24.2 93.5 
*, Ornithine transcarbamylase 
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Fig. 1. Phase contrast microphotographs of PHs in culture. Thawed 9MM PHs were seeded at 8 x 103
cells/cm2 in 35-mm dishes (growth area, 9.6 cm2) and co-cultured up to 20 days with 4 x 103 Swiss 3T3 
cells/cm2 in h-HCGM (A-H). Freshly isolated 16F2-PHs were seeded at 8 x 103 cells/cm2 in 35-mm 
dishes, and cultured up to 33 days as in16F1-PHs (I and J). The mark (*) was made on the back surface 
of the dishes on day 1 of culture to monitor the growth of seeded cells. A cell enclosed by dotted line in A 
was selected and monitored for the growth through 20 days by periodically taking phase contrast 
microphotographs. A. Day 4. B. Day 5. C. Day 6. D. Day 7. E. Day 10. F. Day 13. G. Day 17. H. Day 20. 
Arrows in A to H point to some of Swiss 3T3 cells. The size of colony increased gradually during culture. 
The area of colony was 0.0037, 0.0262, and 0.0685 cm2 at 13, 17 and 20 days, respectively. 
Magnification of A to G is the same as in H. Bar in H, 100 µm. I. PHs at 20 days. J. PHs at 33 days. 
Magnification of I is the same as in J. Bar in J, 100 µm
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Fig. 2. Growth ability of CF-PHs.  A. Colony-forming efficiency of PHs in relation to the age of donors. 
PHs were prepared from 3M, 16F1, 16F2, 45F, 53M, 58F, 61F, 63F, 63M, 68F, and 72M2, and were seeded 
at the density of 8 x 103 cells/cm2, except PHs from 16F1 which were seeded at 4 x 103 cells/cm2, and 
cultured for 20 days as in Fig. 1. The colony-forming efficiency was determined as the ratio (%) of number 
of colonies formed at 20 days of culture to that of th
solid line represents the statistically significant regression curve (y = -0.001x + 0.076, r2 = 0.714).  B. 
Serial subcultivation of CF-PHs. PHs from 5 donors (3M, 12M, 16F2, 63M, and 72M1) were seeded at the 
density of 8 x 103 cells/cm2, and cultured as in Fig. 1. They were detached as CF-PHs from the dishes at 
appropriate time points when they became confluent and subjected to subcultures, the seeding density being 
at 4 x 103 cells/cm2 at each passage. Open rhombuses, 3M-CF-PHs; closed squares, 12M-CF-PHs; open 
circles, 16F2-CF-PHs; open triangles, 63M-CF-PHs; open squares, 72M1-CF-PHs. PDT at passage 4 of 
CF-PHs from 3M, 12M, 16F2, 63M, and 72M1 was 220.3, 170.7, 223.6, 649.4, and 1,162.0 h, respectively. 
Cultures of 3M-, 12M-, and 16F2-CF-PHs were terminated at passages marked by *, because they failed to 
grow thereafter. Cultures of 63M- and 72M1-CF-PHs were terminated at passages marked by **, because 
PDT became large thereafter.
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Fig. 3. Phenotypes of CF-PHs.  3M- and 12M-PHs were serially subcultured. 3M-CF-PHs at passage 2 
were cultured up to 13 days when the cells were still in pre-confluence and subjected to 
immunocytochemical staining (A and B). 12M-CF-PHs at passage 3 were cultured for 27 days when the 
cells were confluent and were subjected to immunocytochemistry (C - I), in which double 
immunocytochemistry for 1-AT and CK19 was done in G - I.  A. CK8-staining. Most cells were CK8+.  
B. CK19-staining. All the cells were CK19+.  C. ALB-staining. Most cells are ALB+. Especially 
hepatocytes in condensed regions indicated with * are strongly positive. * is similarly marked in D - I.  
D. 1-AT staining. 1-AT+ cells are present in condensed regions.  E. AFP-staining. All the cells were 
AFP-.  F. Negative staining for C, D, and E. Magnification of A to E is the same as in F. Bar in F, 100 
µm.  G. Red color shows anti-human 1-AT rabbit antibodies visualized by goat Texas red-anti-rabbit 
IgG.  H. Green color shows anti-human CK19 mouse antibodies visualized by goat FITC-conjugated 
anti-mouse IgG.  I. Photographs of G and H are merged. 1-AT+ cells are negative for CK19. 
Magnification of G and H is the same as in I. Bar in I, 100 µm.
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Fig. 4. Phase contrast microphotographs of CF-PHs and HepG2 cultured in monolayers and spheroids.  A. 
12M-CF-PHs at 3 passages were detached from dishes and inoculated at 105 cells/cm2 in 35-mm wells and 
cultured for 7 days. They showed a typical hepatocyte-like morphology in condensed regions (arrows).  B. 
HepG2 cells were similarly cultured in wells as in A.  C. 12M-CF-PHs at 3 passages similarly cultured as 
in A, but on Matrigel.  D. HepG2 cells were similarly cultured as in A, but on Matrigel. Magnification of 
A through C is the same as in D. Bar in D, 100 µm. 
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Fig. 5. ALB secretion by CF-PHs in monolayer- and spheroid-culture. 12M-CF-PHs at 3 passages were 
harvested from dishes at 22-58 days in culture and were cultured in monolayers (ML, open bars) and 
spheroids (SP, closed bars) as in Fig. 4 up to 7 days. The cells were refilled with fresh media at 1 day and 
cultured for additional 3 days (Day 1-4). Then, the cells were refilled with fresh media and cultured further 
for 3 days (Day 4-7). Media were collected at 4 and 7 days, and were used to quantify ALB of Day 1-4 and 
Day 4-7, respectively. The level of ALB secretion was determined as ALB secreted during 3 days in culture 
per 1 mg protein of CF-PHs in culture. CF-PHs in monolayer and in spheroid secreted ALB at 5.0 ± 2.2 and 
5.0 ± 3.9 ng/3 days/1 µg cell protein through 1 to 4 days, and 13.1 ± 0.6 and 33.2 ± 2.7 ng/3 days/1 µg cell 
protein through 4 to 7 days, respectively. Each value represents the mean ± S.D. (n=3). * represents the 
statistical difference at P<0.05.  
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Fig. 6. Expression of mRNAs of ALB, HNF4, AFP, and CYPs in monolayer- and spheroid-culture of 
CF-PHs. A. Comparison of gene expression between fresh and C-T PHs. PHs were prepared from 3 
different donors (51M, 53M2, and 68F), and their aliquots were subjected to C-T. Fresh and C-T cells 
were used to quantify mRNAs of GAPDH, ALB, HNF4, AFP, and CYPs by real-time RT-PCR. We 
calculated the mean ratio of copy number of these mRNAs of C-T PHs to that of fresh ones. Each value 
represents the mean ± S.D. (n=3). B through F. mRNA expression in CF-PHs in monolayer- and 
spheroid-culture. Fresh 12M-PHs were subjected to C-T. Aliquots of C-T PHs were used for RNA 
extraction and the remaining was subcultured up to 3 passages. CF-PHs at 3 passages and HepG2 cells 
were cultured in monolayer (ML) and spheroid (SP) for 7 days and were determined for mRNA 
expression by RT-PCR. B. GAPDH mRNA. C. ALB mRNA. D. HNF4 mRNA. E. AFP mRNA. F. CYPs 
mRNA. Values represent the mean ± S.D. (n=3). * and ** indicate statistical significance of difference 
t-test at P<0.05 and P<0.01, respectively. 
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III-(1). In vitro Evaluation of Cytochrome P450 and Glucuronidation Activities in 
Hepatocytes Isolated from Liver-Humanized Mice
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Abstract
Cryopreserved human (h-) hepatocytes are currently regarded as the best in vitro model for predicting 
human intrinsic clearance of xenobiotics. Although fresh h-hepatocytes have greater plating efficiency on 
dishes and greater metabolic activities than cryopreserved cells, performing reproducible studies using 
fresh hepatocytes from the same donor and having an on demand  supply of fresh hepatocytes are not 
possible. In this study, cryopreserved h-hepatocytes were transplanted into albumin 
enhancer/promoter-driven, urokinase-type plasminogen activator, transgenic/severe combined 
immunodeficient (uPA/SCID) mice to produce chimeric mice, the livers of which were largely replaced 
with h-hepatocytes. We determined whether the chimeric mouse could serve as a novel source of fresh 
h-hepatocytes for in vitro studies. h-Hepatocytes were isolated from chimeric mice (chimeric hepatocytes),  
and cytochrome P450 (P450) activities were determined. Compared with cryopreserved cells, the P450 
(1A2, 2C9, 2C19, 2D6, 2E1, 3A) activities of fresh chimeric hepatocytes were similar or greater. Moreover, 
ketoprofen was more actively metabolized through glucuronide conjugates by fresh chimeric hepatocytes 
than by cryopreserved cells. We conclude that chimeric mice may be a useful tool for supplying fresh 
h-hepatocytes on demand that provide high and stable phase I enzyme and glucuronidation activities. 
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Introduction
-hepatocytes), created using 
urokinase-type plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice (1), were 
previously established previously, and the expression of both cytochrome P450 enzymes (P450s, CYPs) 
and phase II enzymes in the liver of these chimeric mice, as well as in vivo induction of P450, were 
examined (1-4).  
P450 has been found to play an important role in the metabolism of xenobiotics, including drugs. 
Indeed, approximately 80% of oxidative metabolism is catalyzed by P450s (5), and to predict 
pharmacokinetics and drug interactions precisely, investigation of the pharmacokinetics of a P450 substrate 
using chimeric mice would be of considerable value. 
 Species differences are known to exist in the metabolism of ketoprofen (6). Ketoprofen is a 
propionic acid-class nonsteroidal anti-inflammatory drug with analgesic and antipyretic effects. Rat and 
mouse P450s primarily metabolize ketoprofen to hydroxyketoprofen (6,7). In humans, ketoprofen is 
primarily metabolized by UDP-glucuronosyltransferase (UGT) and is converted to ketoprofen glucuronides 
(8). Recently, it was demonstrated that when chimeric mice were administered ketoprofen, glucuronide 
conjugates were detected in their sera and bile. However, these conjugates are minor products; ketoprofen 
was primarily hydrolyzed in mice and the main metabolites were hydrolyzed ketoprofen and 
glucuronide-conjugated ketoprofen (7). 
The metabolism of chemical entities has been examined using animals in the laboratory, but this 
approach fails to address differences in drug metabolism that exist between animal species. Because of the 
species differences in metabolic abilities, fresh h-hepatocytes are a better model for predicting the 
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metabolism of drugs in the human body. For technical reasons, preparing fresh h-hepatocytes ahead of time 
and performing reproducible studies using the same donor are not possible. Thus, cryopreserved 
h-hepatocytes have been used, but they are compromised on thawing, resulting in decline and alteration of 
their normal function. Additionally, h-hepatocytes exhibit large individual differences in P450 activities. 
The differences might be due to real individual differences and/or the cryopreserving and thawing 
conditions. 
     We hypothesized that these practical problems in using h-hepatocytes for in vitro drug testing could 
be addressed if h-hepatocytes isolated from chimeric mouse livers exhibited human-type drug metabolism 
capacities in vitro. In the present study, we first determined the yield, viability, and purity of isolated 
h-hepatocytes from chimeric mice (chimeric hepatocytes). We compared the P450 activities of fresh and 
cryopreserved chimeric hepatocytes and assessed glucuronide activities toward ketoprofen using fresh and 
cryopreserved chimeric hepatocytes and cryopreserved donor hepatocytes. 
We demonstrate that the chimeric mouse liver is a useful tool that can supply fresh hepatocytes retaining 
high P450 and UGT activities and allowing reproducible assays using hepatocytes derived from the same 
donor. 
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Materials and methods
Materials: Phenacetin, tolbutamide, S-mephenytoin, dextromethorphan, chlorzoxazone, testosterone, 
ketoprofen, and Krebs-Henseleit buffer (KHB) were purchased from Sigma-Aldrich (St. Louis, MO). 
Coumarin and midazolam were obtained from Wako Pure Chemical Industries (Osaka, Japan). All other 
chemicals and solvents were of the highest or analytical grade commercially available.  
     Generation of Mice with Humanized Livers: The present study was approved by the ethics 
committee of PhoenixBio Co., Ltd. and the Hiroshima Prefectural Institute of Industrial Science and 
Technology Ethics Board.  
     Cryopreserved h-hepatocytes from three donors (4YF, a 4-year-old Caucasian girl; 6YF, a 6-year-old 
African-American girl; and 2YM, a 2-year-old Caucasian boy) were purchased from BD Biosciences (San 
Jose, CA). Three (donor 4YF), 17 (donor 6YF), and 4 (donor 2YM) chimeric mice with humanized livers, 
generated by a method described previously, were used (1). The concentration of human albumin (hAlb) in 
the blood of the chimeric mice and the replacement index (RI, the rate of hepatocyte replacement from 
mouse to humans) were well correlated (1). In the current study, we used 11 15-week-old male and female 
chimeric mice with approximately 11 14 mg/mL hAlb in mouse blood (RI >70%); uPA/SCID mice were 
used as controls. 
     Isolation of Hepatocytes from Chimeric Mouse Liver, SCID Mouse Liver, and Human Liver 
Tissue: Hepatocytes were isolated from the 4YF-, 6YF-, and 2YM-chimeric mice using a two-step 
collagenase perfusion method. The liver was perfused at 38°C for 10 min at 1.5 mL/min with Ca2+-free and 
Mg2+-free -HBSS) containing 200 µg/mL ethylene glycol tetraacetic 
acid (EGTA), 1 mg/mL glucose, 10 mM N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid (HEPES), 
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and 10 µg/mL gentamycin. The perfusion solution was then changed to CMF-HBSS containing 0.05% 
collagenase (Wako Pure chemical Industries), 0.6 mg/mL CaCl2, 10 mM HEPES, and 10 µg/mL 
gentamycin, and perfusion was continued for 17-23 min at 1.5 mL/min. The liver was dissected and 
transferred to a dish; liver cells were gently disaggregated in the dish with CMF-HBSS containing 1% 
bovine Alb, 10 mM HEPES, and 10 µg/mL gentamycin. The disaggregated cells were centrifuged three 
times (50×g
medium (DMEM), 10% fetal bovine serum (FBS), 20 mM HEPES, 44 mM NaHCO3, and antibiotics (100 
IU/mL penicillin G and 100 µg/mL streptomycin). Cell number and viability were assessed using the 
trypan blue exclusion test.  
   Normal liver tissues were obtained from the resected liver of nine patients (51-, 53-, and 64-year-old 
men and a 68-year-old woman for plating efficiency; 54-, 57-, and 75-year-old men for P450 activity; and 
55- and 69-yearold women for screening of monoclonal antibodies) after receiving consent prior to surgery, 
in accordance with the 1975 Declaration of Helsinki. Hepatocytes were isolated via two-step collagenase 
perfusion and low-speed centrifugation(1). Aliquots of freshly isolated hepatocytes from four individuals, 
used for determining plating efficiency, were suspended at 1 2× 107 cells/mL/vial in cryopreservation 
solution (Cellbanker; Juji Field, Inc., Tokyo, Japan), cryopreserved using a program freezer (Kryo-10 
Series III; Planer Products Ltd., Sunbury-on Thames, Middlesex, UK), and kept in liquid nitrogen. To 
measure the plating efficiency of the hepatocytes, 4YFchimeric hepatocytes and hepatocytes from human 
livers were inoculated onto 13.5-mm Celldesks (Sumitomo Bakelite, Tokyo, Japan) in 24-well plates (BD 
Biosciences) for 24 h, followed by fixation with ethanol and staining with hematoxylin and eosin. Adhered 
hepatocytes were counted under the microscope and plating efficiency was calculated by dividing number 
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of adhered cells by the cell number inoculated in a well.
Hepatocytes were isolated from three male uPA (wt/wt)/SCID mice by collagenase perfusion methods 
(9).  They were used for in vitro glucuronidation activity studies 
Purification of h-hepatocytes from total hepatocytes of the chimeric mouse livers: A Fischer 344 
rat was immunized intraperitoneally three times (once a week) with 107 mouse hepatocytes (m-hepatocytes) 
of SCID mice as an antigen, and injected with a booster of 2.5 × 107 m-hepatocytes at 3 weeks after the last 
immunization. Hybridomas were obtained by conventional methods and screened on immunohistochemical 
sections using m- and h- (from a 55-year-old woman) liver tissues. Frozen h- and m- liver sections were 
incubated with hybridoma supernatants and fluorescein-labeled anti-rat IgG antibodies (Alexa Fluor 594; 
Molecular Probes, Eugene, OR). Supernatants from 10 hybridoma clones were reacted with the plasma 
membrane of m-hepatocytes, but not with h-hepatocytes on the sections. The reactivity of each of the 
supernatants to the cell surface was determined with a fluorescence-activated cell sorter (FACS) as follows. 
Isolated m- and h- (69-year-old woman) hepatocytes were incubated with the supernatants and fluorescein 
isothiocyanate (FITC)-conjugated second antibodies (Alexa Fluor 488; Molecular Probes) and analyzed 
with a FACS Vantage SE (BD Biosciences) using a 100-µm nozzle. Fluorescence excited at 488 nm was 
measured through a 530-nm filter (FL1) with 4-decade logarithmic amplification. A hybridoma clone was 
selected as the clone that produced antibodies reactive to the cell surface of m-hepatocytes, but not 
h-hepatocytes. The antibody was purified from the culture medium of the hybridoma cells by protein G 
affinity column or ion exchange chromatography; the antibody was named 66Z. Isolated h-hepatocytes 
from chimeric mice were contaminated with m-hepatocytes. To remove the m-hepatocytes, 
6YF-hepatocytes isolated from the chimeric mice were incubated with the 66Z antibody, washed with 
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DMEM containing 10% FBS, and incubated with Dynabeads M450-conjugated sheep anti-rat IgG (Dynal
Biotech, Milwaukee, WI) in a tube for 30 min on ice. The tube was placed in Dynal MPC-1 (Dynal 
Biotech) for 1 2 min to remove 66Z-positive (66Z+) m-hepatocytes. Enriched h-hepatocytes were collected 
as 66Z-negative (66Z-) cells. Aliquots of chimeric hepatocytes from before and after enrichment were 
incubated with FITC conjugated 66Z antibodies, and the proportion of 66Z cells in the h-hepatocytes was 
determined by FACS. 
In vitro metabolic study using hepatocytes and microsomes: For the measurement of the P450 
activities of four fresh and five cryopreserved 6YF-chimeric mice, cryopreserved donor cells (6YF), and 
fresh hhepatocytes from three individuals, suspended hepatocytes (6× 104 cells) were incubated in KHB 
with each of eight substrates specific for seven P450 subtypes (phenacetin for CYP1A2, coumarin for 
CYP2A6, tolbutamide for CYP2C9, S-mephenytoin for CYP2C19, dextromethorphan for CYP2D6, 
chlorzoxazone for CYP2E1, and midazolam and testosterone for CYP3A) in 96-well plates (BD 
Biosciences) for 1 or 2 h (Table 1). The incubated solution was collected and an equivalent volume of 
methanol containing 1 mM niflumic acid (internal standard) was added. After centrifugation (10,000 rpm), 
the supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS)(MDS 
SCIEX; Applied Biosystems, Foster City, CA). The LC system consisted of an HP 1100 system including a 
binary pump, an automatic sampler, and a column oven (Agilent Technologies, Waldbronn, Germany), 
equipped with a Symmetry Shield C18 column (Waters, Tokyo, Japan). The column temperature was 359C. 
The mobile phase was 40% acetonitrile/0.1% formic acid (v/v). The flow rate was 0.3 mL/min. The LC was 
connected to a PE Sciex API2000 tandem mass spectrometer (Applied Biosystems), operated in positive 
electrospray ionization mode. The turbo gas was maintained at 5509C. Nitrogen was used as the nebulizing 
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gas, turbo gas, and curtain gas at 65, 85, and 30 psi, respectively. Parent and/or fragment ions were filtered 
in the first quadrupole and dissociated in the collision cell using nitrogen as the collision gas. The analytical 
conditions for each substrate are shown in Table 2. The experiments were performed in triplicate per mouse, 
and the results are expressed as the average value of three mice or humans. 
To assess changes in the P450 activities of fresh and cryopreserved 2YM-chimeric hepatocytes during 
storage at 49C for 3 and 6 h, fresh and cryopreserved chimeric hepatocytes were prepared from two 2YM 
chimeric mice. The isolated hepatocytes from the chimeric mice were purified by isodensity centrifugation 
(27% Percoll, 7 min, 4ºC) to remove dead hepatocytes. Cells (4× 105 cells) were incubated in KHB with 
four different substrates specific for four P450s (phenacetin for CYP1A2, diclofenac for CYP2C9, 
S-mephenytoin for CYP2C19, and midazolam for CYP3A) in 24-well plates (BD Biosciences) for 2 h 
(Table 1). The incubated solution was collected and the concentration of the metabolites was measured by 
high-performance liquid chromatography (HPLC; Lachome Elite; Hitachi High Technology Co., Tokyo, 
Japan). HPLC was performed at a flow rate of 1.0 mL/min using the CAPCELL PAK C18, UG120 (4.6×
250 mm, 5 µm; Shiseido, Tokyo, Japan) for CYP1A2 and CYP2C19, Inertsil ODS-3 (4.6× 250 mm, 5 µm; 
GL Sciences Inc., Tokyo, Japan) for CYP2C9, and Xterra RP18 (4.6× 150 mm, 5 µm; Waters) for CYP3A. 
Other analytical conditions are shown in Table 3. The measurements were performed in duplicate.  
Liver microsomes were prepared from a 6YF-chimeric mouse and control uPA/SCID mice as described 
previously(10). They were stored at -80ºC until analysis. The protein concentration was determined using a 
Bradford protein assay kit (Bio-Rad, Hercules, CA), using bovine serum albumin as the standard. 
Microsomes from a chimeric mouse liver, pooled microsomes of six uPA/SCID mice, and pooled 
microsomes of 20 human livers (BD Gentest; BD Biosciences) were incubated with the substrates at 37ºC 
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for 5 min following incubation with the reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH) cofactor solution (3.8 mM bNADP+, 9.7 mM glucose-6-phosphate, 9.7 mM MgCl2, 1.2 U/mL 
glucose-6-phosphate dehydrogenase) at 37ºC for 10 or 20 min (Table 1). The incubated solution was 
collected and the concentration of the metabolites was measured by LC-MS/MS. The experiments were 
performed in triplicate per microsome preparation, and the results are expressed as the average value. 
Detection of CYP2A6 gene mutations by the Invader assay: CYP2A6 polymorphism was 
determined by BML, Inc. (Tokyo, Japan). Genomic DNA was isolated from thawed human hepatocytes 
and the DNA was used for determining CYP2A6 polymorphism by the Invader assay (11). 
In vitro glucuronidation activity study using hepatocytes: Ketoprofen metabolism was examined 
using three types of hepatocytes: fresh and cryopreserved 6YF-chimeric hepatocytes, cryopreserved donor 
cells (6YF), and fresh uPA(wt/wt)/SCID mouse hepatocytes. Hepatocytes (4 × 105 cells) suspended in 
KHB were plated in 24-well, non-treated plates (BD Biosciences) and incubated at 37ºC for 15 min. The 
cells were treated with 1 µM ketoprofen at 37ºC for 3 h. The medium was harvested and aliquots of the 
medium were incubated at 37ºC for 4 h with 0.25 M acetic acid buffer as a solvent control (A) and with 
2500 units/mL b-glucuronidase (B). Equivalent 1 N KOH was added into (B) and incubated at 80ºC for 3 h 
(C). After incubation, an equivalent of methanol containing 1 µM niflumic acid (as an internal standard) 
was added. After centrifugation (10,000 rpm), the supernatant was subjected to LC-MS/MS. 
The relevant concentrations can then be obtained: 
[Concentration of ketoprofen in (B)]-[Concentration of ketoprofen in (A)] gives [Concentration 
of ketoprofen-glucuronide]. 
[Concentration of ketoprofen in (C)]-[Concentration of ketoprofen in (B)] gives [Concentration 
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of transferred ketoprofen-glucuronide].
The transferred ketoprofen is the acyl glucuronide positional isomer, formed by acyl migration, which may 
be the glucuronide form transferred from ketoprofen glucuronide during incubation. The experiments were 
performed in triplicate for a given mouse, and the results are expressed as the average value of three 
chimeric mice for fresh chimeric hepatocytes, the average of five chimeric mice for cryopreserved 
hepatocytes, and the average of three uPA(wt/wt)/SCID mice for fresh control mouse hepatocytes. 
 Statistics: The data were analyzed using Statcel2 (OMS Publishing Inc., Tokorozawa, Japan). Results 
are expressed as the mean± SD, and the significance of the difference between two groups was analyzed by 
Student's t-test when data were normally distributed, and by Welch's t-test otherwise. P<0.05 was deemed 
to indicate statistical significance. 
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Results
Yield, viability, and plating efficiency of isolated h-hepatocytes: Hepatocytes from the 4YF-, 6YF-, 
and 2YM-donors were transplanted into uPA/SCID mice, and chimeric mice were obtained bearing the 
respective donor hepatocytes (Table 4). The chimeric mice (4YF, 3 mice; 6YF, 17 mice; 2YM, 4 mice) 
were sacrificed at 54 83 days post-transplantation (Table 4). On the day they were sacrificed, blood was 
collected for the determination of hAlb concentrations (Table 4). Hepatocytes were then isolated by the 
collagenase perfusion method. Numbers (yield) of isolated viable hepatocytes were approximately 2 3× 
107 cells/mouse (Table 4). The viabilities were approximately 60 70% and 50 60% for fresh and 
cryopreserved chimeric hepatocytes, respectively, without Percoll purification. 
The plating efficiency of hepatocytes from the chimeric mice was about 66.6± 3.4% (mean± SD), 
while those of fresh hepatocytes and cryopreserved hepatocytes from human livers were 34.0± 19.3% 
and 9.3± 8.3%, respectively.
Purification of h-hepatocytes isolated from chimeric mice: Chimeric hepatocyte preparations 
consisted of h- and m-hepatocytes. It was found that 17.3± 6.7% of the fresh hepatocytes from 
6YF-chimeric mice were 66Z+ (n=4; Table 4) by FACS analysis. The enriched chimeric hepatocytes 
were found to be 3.3±1.0% 66Z+ (m-hepatocytes; n= 4; Table 4). 
P450 activities of hepatocytes from the chimeric mice: The P450 activities of hepatocytes from 
6YF-chi meric mice were determined using eight substrates (Table 1). The reactions of P450 activities 
with all substrates shown in Table 1 were linear with incubation time. The activities of fresh chimeric 
hepatocytes were compared with cryopreserved chimeric hepatocytes and cryopreserved donor cells. 
Three experiments were performed and the means± SD are given in Figure 1. CYP1A2, 2C19, and 2D6 
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activities in fresh chimeric hepatocytes were approximately twice those in cryopreserved cells (Fig. 1). 
CYP2A6, 2C9, 2E1, and 3A activities in fresh chimeric hepatocytes were similar to those of 
cryopreserved hepatocytes (Fig. 1). The activities of cryopreserved donor cells (6YF) were lower than 
those of cryopreserved 6YF-chimeric hepatocytes in CYP1A2, 2C19, and 3A (midazolam); higher in 
CYP2A6 and 2E1; and similar in CYP2C9, 2D6, 3A (testosterone; Fig. 1). Compared with CYP2A6 
activities of two of the three fresh hepatocytes, CYP2A6 activity was extremely low in the chimeric 
hepatocytes (Fig. 1). Interestingly, the Invader assay revealed that donor 6YF had the *1/*4 CYP2A6 
polymorphism; livers with the *1/*4 polymorphism in CYP2A6 are known to show low CYP2A6 
activity (12). We concluded that the low CYP2A6 activity was due to the *1/*4 polymorphism of donor 
6YF. Three kinds of fresh h-hepatocytes were also examined for P450 activity. One of the three samples 
did not show CYP1A2 or 2C19 activity. Large individual differences were observed among the three in 
CYP2A6, 2C9, and 2E1 activities. The activities of CYP1A2, 2C19, 2D6, and 3A in fresh h-hepatocytes 
were lower than those in fresh chimeric hepatocytes. 
We determined changes in the P450 activities of fresh and cryopreserved 2YM-chimeric hepatocytes 
after Percoll purification during storage at 49C after isolation and thawing, respectively. CYP1A2, 2C9, 
2C19, and 3A activities did not change for up to 6 h after isolation or thawing (Fig. 2). CYP1A2, 2C19, 
and 3A activities were lower in cryopreserved chimeric hepatocytes, and CYP2C9 activity was similar 
compared to fresh chimeric hepatocytes at 0 h after isolation or thawing (Fig. 2). The results were 
reproducible and are similar to those in Figure 1. 
Contribution of m-hepatocyte contamination in chimeric hepatocytes to P450 activity: The 
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proportions of m-hepatocytes in the fresh chimeric hepatocytes were approximately 17% and 3% before 
and after purification with 66Z antibodies, respectively, as described above. To determine how the 
contaminating m-hepatocytes affected P450 activities, we measured P450 activities using liver 
microsomes from a 6YF-chimeric mouse, pooled host uPA/SCID mice, and pooled human liver 
microsomes. Except for CYP2D6 and 2E1, P450 activities were similar or lower in uPA/SCID mouse 
liver microsomes than in human pooled microsomes (Fig. 3). Because the activities of CYP2D6 and 2E1 
in uPA/SCID mouse liver microsomes were 50 100% higher than in pooled human microsomes (Fig. 3), 
we considered that m-hepatocytes contaminating the chimeric hepatocytes at around 17% might not 
significantly affect the activities of chimeric hepatocytes. We measured the P450 activity of pre- and 
post-purified chimeric hepatocytes (6YF) using 66Z antibodies. The purified hepatocytes from the 
chimeric mice showed similar P450 activities to unpurified ones, supporting this suggestion (Fig. 1). 
Glucuronide conjugation of ketoprofen in chimeric m-hepatocytes: Glucuronide conjugates were 
detected by in vitro metabolic assay for ketoprofen using fresh and cryopreserved hepatocytes from the 
6YF-chimeric mouse and cryopreserved donor cells (6YF); however, uPA(wt/wt)/SCID mouse 
hepatocytes did not show products of UGT activity. The proportion of nonmetabolized ketoprofen in 
fresh chimeric hepatocytes was similar to that in donor cells and lower than that in cryopreserved 
chimeric hepatocytes (Fig. 4). The proportion of ketoprofen-glucuronide in fresh chimeric hepatocytes 
was significantly higher than that of both cryopreserved chimeric hepatocytes (P<0.05). The transferred 
ketoprofen-glucuronide levels in fresh chimeric hepatocytes were also higher than those of both cells, but 
not significantly so (Fig. 4). From these results, we suggest that the freeze-thaw procedure decreased 
cellular glucuronide conjugation activities on drugs such as ketoprofen. 
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Discussion
Recent studies have revealed that chimeric mice may be a useful model for the examination of drug 
absorption, distribution, metabolism, and excretion (ADME) and drug interactions via enzyme induction 
and inhibition in vivo (1,3,4,7,12 14).  S-Warfarin has been shown to be metabolized to 
S-7-hydroxywarfarin, catalyzed by CYP2C9, and is primarily recovered in urine in humans.15) The 
mass balance and metabolic disposition of Swarfarin in chimeric mice were found to be similar to 
reported human data (14,16). In humans, ketoprofen is primarily metabolized by UGT and converted to 
ketoprofen glucuronides (8). When chimeric mice were administered ketoprofen, glucuronide conjugates 
were detected in their sera and bile (7).  By treatment with typical inducers of P450 
(3-methylcholanthrene and rifampicin), human CYP1A and CYP3A4, respectively, were induced in the 
chimeric mouse liver (1,3). After treatment with quinidine, a specific inhibitor of human CYP2D6, the 
area under the curve (AUC) of CYP2D6 metabolites was significantly decreased in the chimeric mice, 
but not in control mice (13). These findings demonstrate that hhepatocytes in the chimeric mouse liver 
had normal human phase I and II enzyme activity, and that the chimeric mice may have advantages in 
studies of ADME and drug interactions. However, no study had examined the metabolic activity of fresh 
h-hepatocytes isolated from chimeric mice. In the present study, we determined whether the chimeric 
mouse could be a useful source of fresh hhepatocytes for in vitro metabolic studies. 
The metabolic capacities of fresh and corresponding cryopreserved hepatocytes from several donors 
have been compared by testosterone hydroxylation, 7-ethoxyresorufin-O-deethylase (EROD), and 
7-ethoxycoumarinO-deethylase (ECOD). These activities were found to be lower in cryopreserved 
hepatocytes than in fresh ones (17,18). Phase II enzyme activities, GST, UGT toward 
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4-methylumbelliferone (MUF), and sulfotransferase (SULT) were also significantly reduced after 
cryopreservation of h-hepatocytes, whereas the activity of UGT toward 4-hydroxybiphenyl (HOBI) and 
that of SULT were similar to those measured in fresh h-hepatocytes.17) Despite the observed reductions 
of these enzyme activities, cryopreserved h-hepatocytes are regarded as the best in vitro model for use in 
predicting human intrinsic clearance of xenobiotics (19). This is because ahead-of-time experimental 
planning using fresh h-hepatocytes and attaining reproducible studies using the same donor of fresh 
h-hepatocytes is not feasible. Additionally, because large individual variations are known to exist among 
h-hepatocytes, pooled hepatocytes derived from several donors could help eliminate such individual 
variation, but such pooling of fresh h-hepatocytes is not possible. Here, we compared the P450 activities 
of fresh and cryopreserved chimeric hepatocytes originating from the same donor, and fresh 
h-hepatocytes from human livers. Results indicated that CYP1A2, 2C19, and 2D6 activities declined, 
while CYP2A6, 2C9, 2E1, and 3A activities were not affected by the freeze-thaw procedure. Fresh and 
cryopreserved chimeric h-hepatocytes were used for the determination of ketoprofen glucuronidation. 
Concentrations of ketoprofen-glucuronide and transferred ketoprofen-glucuronide were higher in fresh 
chimeric hepatocytes than in their cryopreserved counterparts. Chimeric hepatocytes from the same 
donor showed smaller variations in P450 activities than fresh h-hepatocytes from different individuals 
(Fig. 1). These results indicated that fresh chimeric hepatocytes may address the problem of individual 
differences in fresh h-hepatocytes. Additionally, the fresh and cryopreserved chimeric hepatocytes tested 
retained P450 (CYP1A2, 2C9, 2C19, and 3A) activities for at least 6 h. These studies demonstrated that 
chimeric mice can provide fresh h-hepatocytes ahead of time, making reproducible studies using the 
same donor possible. 
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The decreased metabolism in cryopreserved hepatocytes could be attributable to two mechanisms: 
inactivation of P450 enzymes and loss of the cofactor NADPH due to cell membrane damage (20). The 
addition of a NADPH-generating system to the incubation mixture has been shown to increase 
benzo[a]pyrene metabolite formation by cryopreserved rat hepatocytes to approximately the level of 
freshly isolated rat hepatocytes (21). When cryopreserved rat hepatocytes were purified by Percoll 
centrifugation after thawing, to remove dead and membrane-damaged cells, benzo[a]pyrene metabolism 
recovered to equal that of fresh rat hepatocytes (21). The decline in phase II enzyme activities has also 
been shown to be overcome by Percoll centrifugation, but not completely to the level of freshly isolated 
-diphosphoglucuronic acid (UDPGA) and 
adenosine - -phosphosulfate (PAPS) to cryopreserved rat hepatocytes improved 
7-hydroxycoumarin-glucuronide and 7-hydroxycoumarin-sulfate formation to levels observed in fresh 
hepatocytes (22). The UDPGA and PAPS synthesis machineries may be damaged during freezing and 
thawing. Fresh or cryopreserved chimeric hepatocytes would be useful in clarifying the mechanisms 
underlying the decline in metabolic activities after freezing and thawing. The results of this study also 
suggest that fresh chimeric hepatocytes are useful for testing phase I and II reactions, including 
glucuronidation, without the need for Percoll purification or the addition of cofactors. 
Chimeric hepatocytes contain about 17% of m-hepatocytes, and 66Z antibodies react specifically 
with mhepatocytes. We purified h-hepatocytes from the chimeric hepatocytes by 66Z rat IgG and 
magnetic bead-conjugated anti-rat IgG antibodies. After the magnetic removal of m-hepatocytes, the 
proportion of m-hepatocytes decreased to approximately 3%. We measured the P450 activities of 
microsomes isolated from the chimeric mouse and pooled microsomes from uPA/SCID mice and human 
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livers using the same substrates as those used in the cell suspension study. Because we were not able to 
obtain microsomes from the donor of the chimeric mice (6YF), pooled human microsomes were used for 
this study. Except for CYP2D6 and 2E1, the activities of uPA/SCID mouse liver microsomes were 
similar to, or lower than, those of pooled human liver microsomes. The activities of CYP2D6 and 2E1 in 
uPA/SCID mouse liver microsomes were 50 100% higher than those of pooled human liver microsomes, 
respectively. We also found that P450 activities were similar between pre- and postpurified chimeric 
hepatocytes. From these results, we deduced that m-hepatocytes contaminating the chimeric hepatocytes 
might not significantly affect the activities of chimeric hepatocytes. 
Gender differences in CYP3A4 activities have been reported when using cryopreserved human 
hepatocytes (23). We assumed that P450 activities were independent of the gender in recipient uPA/SCID 
mice, because we recently showed that there was no significant difference in P450 activity (CYP1A2, 
2C9. 2C19, 2D6, and 3A) between microsomes from male and female chimeric mice (24). In the present 
study, hepatocytes isolated from both male and female chimeric mice were used, and there was no 
difference in P450 or UGT activity between them (data not shown); however, the number of animals was 
limited. 
Non-platable 4YF- and 6YF-donor cells were engrafted and grown in the uPA/SCID mice and 
hepatocytes were isolated from the livers using the collagenase perfusion method. Fresh chimeric 
hepatocytes adhered well onto the culture dishes, compared with fresh and cryopreserved h-hepatocytes. 
This suggests that fresh chimeric hepatocytes would be suitable for P450 induction and toxicity studies 
that are usually performed with plated cells. 
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Cryopreserved h-hepatocytes isolated from the chimeric mice were demonstrated to be useful for 
evaluating the induction of CYP1A2 and 3A4 (25); in addition, CYP1A2 and 3A4 mRNA induction and 
expression from three different donor hepatocytes were reproduced in cryopreserved chimeric 
hepatocytes (26). Due to the higher plating efficiency of fresh hepatocytes compared to cryopreserved 
cells, fresh chimeric hepatocytes would be useful for evaluating the human P450 induction abilities of 
xenobiotics. 
We conclude that fresh and reproducible h-hepatocytes isolated from chimeric mice could be a useful 
tool in predicting the pharmacokinetics of chemical entities in addition to in vivo chimeric mouse studies. 
Comparative in vitro and in vivo studies using chimeric mice with the same donor could generate 
abundant data for resolving poorly understood phenomena and mechanisms. 
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Tables and figures 
Table 1.  




















CYP1A2 Phenacetin O-deethylase Phenacetin (15) Acetaminophen 2 2 PB 20 
CYP2A6 Coumarin 7-hydroxylase Coumarin (8) 7-Hydroxycoumarin 2 - TB 20 
CYP2C9 
Tolbutamide 4-hydroxylase Tolbutamide (150) Hydroxytolbutamide 2 - TB 10 
-hydroxylase Diclofenac (100) 4-Hydroxydiclofenac - 2 - -
CYP2C19 S-Mephenytoin 4'-hydroxylase S-Mephenytoin (20) (±)-4'-Hydroxymephenytoin 2 2 PB 20 
CYP2D6 Dextromethorphan O-demethylase Dextromethorphan (8) Dextrorphan 2 - PB 20 
CYP2E1 Chlorzoxazone 6-hydroxylase Chlorzoxazone (100) 6-Hydroxychlorzoxazone 2 - PB 20 
CYP3A 
Midazolam 1'-hydroxylase Midazolam (10) 1'-Hydroxymidazolam 1 2 PB 10 
-hydroxylase Testosterone (50) -Hydroxytestosterone 2 - PB 10 
*TB, Tris-HCl buffer (pH 7.5); PB, potassium phosphate buffer (pH 7.4). 
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Table 2.  















Collision cell  







CYP1A2 Acetaminophen Positive 40 25 7 10 5000 152.2 110.3
CYP2A6 7-Hydroxycoumarin Positive 80 30 7 10 4200 162.8 107.2
CYP2C9 Hydroxytolbutamide Positive 40 25 7 10 5000 286.9 171.3
CYP2C19 (±)- -Hydroxymephenytoin Positive 80 25 7 10 4200 234.9 150.1
CYP2D6 Dextrorphan Positive 120 40 7 10 4200 259.0 200.2
CYP2E1 6-Hydroxychlorzoxazone Negative 80 25 7 10 4200 184.1 120.0
CYP3A -Hydroxytestosterone Positive 60 25 7 10 4200 305.9 270.3
-Hydroxymidazolam Positive 100 40 7 10 5000 341.6 203.3
Ketoprofen Ketoprofen Positive 80 35 7 10 5000 255.5 104.9
- 62 - 
Table 3.  
Analytical conditions of HPLC for CYP1A2, 2C9, 2C19, and 3A assays 
Enzymes 
measured 















95 50 mM  
PB (pH 4.0) 





50 0.5% (v/v)  
AAAS 
Methanol containing  
0.5% (v/v) acetic acid 
40 (0) 90 (30) 
90 (35) 40 (36) 
50 280 
CYP2C19 (±)- -Hydroxymephenytoin Phenobarbital 
sodium 
95 50 mM  
PB 
Acetonitrile Isocratic mode 
 (A/B=80/20) 35 240 
CYP3A -Hydroxymidazolam 
Phenacetin 
50 10 mM  
PB (pH 7.4) 
Acetonitrile/methanol  
mixture (7/5, v/v) 
30 (0) 30 (5) 60 (17) 
60 (25) 30 (26) 
40 263 
* PB, potassium phosphate buffer; AAAS, acetic acid aqueous solution. 
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Table 4.  
Hepatocytes used for the experiments 
Purpose Origin Fresh or  
cryopreserved 
n  
(sex of host 
animals or 
patients) 
hAl in  
mouse blood  
(mg/mL) 
Yield of  
hepatocytes  
(×107 cells) 
Viability (%) Ratio of 





Plating efficiency Chimeric mouse (4YF) Fresh 3 (M: 1, F: 2) 11.5±3.6 2.90±2.7/mouse 63.9±6.5 N.D.*4) N.D. 
Human liver (51 68-year-old) Fresh 4 (M: 3, F: 1) - 0.98±0.4/g liver 87.9±8.2 - -
Cryopreserved 4 (M: 3, F: 1) - - 56.2±7.5*5) - -
CYP activities Chimeric mouse (6YF) Fresh 4*1) (F) 11.8±0.6 1.78±0.9/mouse 61.8±6.9 17.3±6.7 3.3±1.0
Cryopreserved 5*2) (M: 2, F: 3) 12.6±2.1 - 60.5±10.6*5) 5.8±4.7*5) 2.1±1.0*5)
Human liver (54 75-year-old) Fresh 3 (M: 3) - 0.43±0.4/g liver 96.1±2.4 - -
Donor cell (6YF) Cryopreserved 1 (F) - - 71.1 - -
CYP activities at 
different time points  
after perfusion or thawing  
Chimeric mouse (2YM) Fresh 2*3) (F) 11.8 3.05*5), 6)/mouse 84.8*5), 6) N.D. N.D. 
Cryopreserved 2*3) (F) 11.8 - 86.4*5), 6) N.D. N.D. 
Glucronide activities Chimeric mouse (6YF) Fresh 3 (F) 13.5±2.9 3.24±1.0/mouse 69.8±11.2 9.8±2.0 -
Cryopreserved 5 (M: 3, F: 2) 13.4±2.4 - 50.7±5.1*5) 12.5±7.2 -
Donor cell (6YF) Cryopreserved 1 (F) - - 86.7 - -
uPA (wt/wt)/SCID mouse Fresh 3 - 1.51±0.3/mouse 73.2±4.7 - -
*1) Hepatocytes from one of four mice were used for CYP1A2, 2C9, and 3A (testosterone), and those from another were used for CYP2A6, 2C19, 2D6, 2E1, and 3A (midazolam). 
Hepatocytes from two mice were used for all tested P450s. 
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*2) Hepatocytes from one of five mice were used for CYP1A2, 2C9, and 3A (testosterone); those from a second mouse were used for CYP2A6, 2C19, and 2E1; those from a third 
mouse were used for CYP2C19, 2D6, 3A (midazolam); and those from a fourth mouse were used for tested P450s except for CYP2C19.  
Those from a fifth mouse were used for all tested P450s. 
*3) Hepatocytes from one of two mice were used for CYP1A2 and 3A, and those from the second mouse were used for CYP2C9 and 2C19. 
* 4) Not determined. 
*5) Data after thaw. 
*6) Data after purification with Percoll. 
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Fig. 1. P450 activities of fresh and cryopreserved chimeric hepatocytes, cryopreserved donor 
hepatocytes, and fresh h-hepatocytes, determined by LC-MS/MS
Hepatocytes were isolated from 6YF-chimeric mice. Aliquots of the isolated hepatocytes were frozen 
with a programmed freezer. Aliquots of fresh and thawed cryopreserved chimeric hepatocytes were 
purified with 66Z antibodies by magnetic sorting. Cryopreserved donor hepatocytes (6YF) for the 
chimeric mice were thawed. Fresh h-hepatocytes were isolated from resected livers after surgery from 
three patients. Eight kinds of suspended hepatocytes were incubated with eight substrates specific for 
seven P450s (Table 1): (A) 1A2, (B) 2A6, (C) 2C9, (D) 2C19, (E) 2D6, (F) 2E1, (G) 3A, midazolam, and 
(H) 3A, testosterone. The incubated medium was analyzed for each metabolite by LC-MS/MS (Table 2) 
and the metabolic activity of each P450 is shown as pmol/106 cells/min. Data in fresh and cryopreserved 
chimeric hepatocytes are shown as means± SD of metabolite concentrations of three different chimeric 
mice. *p<0.05, **p<0.01. ND, not detected. 
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Fig. 2. Time course of P450 activities in fresh and cryopreserved chimeric hepatocytes after 
isolation or thawing, respectively, as 
assessed by HPLC 
Fresh and cryopreserved 2YM-chimeric hepatocytes were stored after isolation and thawing, respectively, 
at 49C for 3 and 6 h. The fresh and cryopreserved chimeric hepatocytes were purified by Percoll 
isodensity centrifugation after isolation or thawing. Fresh and cryopreserved chimeric hepatocytes, just 
after purification (0 h) and after storage for 3 h and 6 h, were treated with four substrates specific for four 
P450s (Table 1): (A) 1A2, (B) 2C9, (C) 2C19, and (D) 3A. The incubated medium was used to analyze 
each metabolite by HPLC; the metabolic activity of each P450 is shown as pmol/106 cells/min (Table 3). 
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Fig. 3. P450 activities of liver microsomes from chimeric mice, uPA/SCID mice, and human livers 
as determined by LC-MS/MS 
Microsomes from a 6YF-chimeric mouse and pooled microsomes of uPA/SCID mice and human livers 
were treated with eight substrates specific for seven P450s (Table 1), and the metabolite concentrations 
were measured by LC-MS/MS; the metabolic activity of each P450 is shown as pmol/mg protein/min 
(Table 2): (A) 1A2, (B) 2A6, (C) 2C9, (D) 2C19, (E) 2D6, (F) 2E1, (G) 3A, midazolam, and (H) 3A, 
testosterone. 
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Fig. 4. Glucuronidation of ketoprofen in fresh and cryopreserved chimeric hepatocytes, 
uPA(wt/wt)/SCID mouse hepatocytes, and cryopreserved donor hepatocytes, as determined by 
LC-MS/MS 
Fresh and cryopreserved chimeric hepatocytes, uPA(wt/wt)/SCID mouse hepatocytes, and cryopreserved 
donor hepatocytes (6YF) were incubated with ketoprofen for 3 h. The conditioned medium was treated 
with b-glucuronidase and 1 N KOH, and the concentration of ketoprofen was measured by LC-MS/MS 
(Table 2): (A) Non-metabolized ketoprofen, (B) Ketoprofen-glucuronide, (C) Transferred 
ketoprofenglucuronide, and (D) other metabolites. The concentrations of ketoprofen-glucuronide and 
transferred ketoprofen-glucuronide were calculated by the formulas indicated in Materials and Methods, 
and the activities were expressed as the ratio of the concentration of ketoprofen or its glucuronide 
conjugate to the ketoprofen concentration at 0 h. The values shown are the means± SD of three or five 
different chimeric mice. *p<0.05, **p<0.01. ND, not detected. 
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III-(2). Culture density contributes to hepatic functions of fresh human hepatocytes 
isolated from chimeric mice with humanized livers: Novel, long-term, functional 
two-dimensional in vitro tool for developing new drugs 
- 71 - 
Abstract
Chimeric mice with humanized livers are considered a useful animal model for predicting human (h-) drug 
metabolism and toxicity. In this study, the characteristics of fresh h-hepatocytes (cFHHs, PXB-cells®) 
isolated from chimeric mice (PXB-mice®) were evaluated in vitro to confirm their utility for drug 
development. cFHHs cultured at high density (2.13 × 105 cells/cm2) displayed stable production of 
h-albumin and cytochrome P450 (CYP) 3A activities for at least 21 days. The mRNA expression levels of 
10 of 13 CYP, UDP-glucuronosyltransferase (UGT), and transporters were maintained at >10% of the 
levels of freshly isolated cFHHs after 21 days. From 1 week, many bile canaliculi were observed between 
cFHHs, and the accumulation of the multidrug resistance-associated protein and bile salt export pump 
substrates in these bile canaliculi was clearly inhibited by cyclosporin A. Microarray analysis of cFHHs 
cultured at high density and at low density (0.53 × 105 cells/cm2) revealed that high density culture 
the high CYP, UGT and transporter gene expressions of cFHHs. These results strongly suggest that cFHHs 
could be a novel in vitro tool for drug development studies. 
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Introduction
Drug metabolism, transporter, and hepatotoxicity tests for new chemical entities have been 
performed using cryopreserved human (ch-) hepatocytes as the gold standard. Although fresh human (h-) 
hepatocytes retain higher metabolic activities to some extent than ch-hepatocytes [1, 2], an on-demand 
supply and reproducible experiments using fresh h-hepatocytes from the same donor are impossible. 
Generally, when rat hepatocytes are inoculated at high density on dishes (>2  105 cells/cm2), 
attachment efficiency decreases due to overlaying [3]. In our experience, when rat or mouse (m-) 
hepatocytes were inoculated at high density on collagen-coated dishes (>2 105 cells/cm2), hepatocytes 
detached from the dishes because cell-cell adhesion was stronger than cell dish adhesion. Therefore, in 
general, fresh hepatocytes have been preconfluently inoculated for metabolism or toxicology studies. 
However, cytochrome P450 enzyme (CYP) mRNA expression and activity in preconfluently cultured 
hepatocytes promptly decline [4, 5]. Therefore, studies of drug metabolism have been performed using 
h-hepatocytes suspended for 1 or 2 hours. In addition, because fresh m-hepatocytes and thawed 
ch-hepatocytes do not remain viable for longer than 1 week in traditional two-dimensional (2D) cultures, 
novel 2D culture system [6], sandwich 2D cultures [7], or three-dimensional cultures are needed for 
long-term experiments. 
In the last decade, chimeric mice with humanized livers have been developed using several host 
mice, including urokinase-type plasminogen activator/severe combined immunodeficiency (uPA/SCID) 
mice [8, 9], Fah(-/-)Rag2(-/-)Il2rg (-/-) mice [10], and NOG-Tg (Alb-UL23) 7-2/ShiJic (TK-NOG) mice 
[11]. We succeeded in the stable and mass production of chimeric mice with humanized livers using 
uPA/SCID mice (PXB-mice®) [8]. The mRNA expression levels of approximately 82% of h-hepatocyte 
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genes from chimeric mice were similar to or within 2-fold of the levels in human liver [12]. Protein 
expression levels of phase I CYPs and transporters in chimeric mouse livers were similar to or within 
4-fold of the levels in human liver [13]. In addition, we recently developed a new type of host mouse, the 
cDNA-uPA/SCID mouse [14]. Chimeric mice generated from cDNA-uPA/SCID mice exhibited improved 
characteristics over those of chimeric mice generated from uPA/SCID mice. The improvements included 
increased body weight and higher stable repopulation rates of h-hepatocytes [14]. Our chimeric mice have 
been utilized for in vivo drug metabolism and pharmacokinetics (DMPK) [15, 16, 17], drug-drug 
interaction [5, 18], and toxicology studies [19, 20, 21]. The chimeric mice also have been used for efficacy 
studies of chemical entities against hepatitis B virus and hepatitis C virus, because the chimeric mice are 
susceptible to these hepatitis viruses [22, 23, 24]. 
We obtained fresh h-hepatocytes (cFHHs, PXB-cells ) from our chimeric mice obtained by a 
collagenase perfusion method [1] and reported that CYP activities of suspended fresh h-hepatocytes and 
ch-hepatocytes from cFHHs were similar [1]. We also reported in vitro and in vivo CYP mRNA induction 
studies using chimeric mice and cFHHs with the same donor hepatocytes [5]. 
Recently, we demonstrated that cultured cFHHs were susceptible to HBV infection and that 
HBV-infected cFHHs can be maintained for more than 3 weeks when the cFHHs were cultured on 
collagen-coated dishes at a high density (2.13  105 cells/cm2) [25]. Therefore, cFHHs have been used for 
in vitro efficacy studies of anti-HBV agents [25]. In those studies, we found that cFHHs can attach to 
collagen-coated dishes in high density cultures without the detachment seen in rodent hepatocytes and can 
be maintained for more than 3 weeks [25]. 
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In the present study, high density 2D-cultures of cFHHs enabled long-term culture of h-hepatocytes 
maintaining CYP, UDP-glucuronosyltransferase (UGT), transporter mRNA expression and the activities of 
CYP3A and multidrug resistance-associated protein (MRP2) transporter and bile salt export pump (BSEP). 
We also evaluated differences in donors and individual chimeric mice using ch-hepatocytes isolated from 
three different donors. Finally, the role of the high density culture condition was determined by microarray 
analysis of cFHHs cultured at high and low density. 
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Materials and methods
Chemicals 
Krebs Henseleit buffer was purchased from Sigma-Aldrich (St. Louis, MO). Midazolam, and 
cyclosporin A (CsA) were obtained from Wako Pure Chemical Industries (Osaka, Japan). 
5(6)-Carboxy-2',7'-dichlorofluorescein diacetate (CDFDA) was purchased from Thermo Fisher Scientific 
(Waltham, MA). 
N-(24-[7-(4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole)]amino- -trihydroxy-27-nor-5 
-cholestan-26-oyl)-2'-aminoethanesulfonate (Tauro-nor-THCA-24-DBD, DBD) was purchased from 
GenoMembrane (Kanagawa, Japan). All other chemicals and solvents were of the highest grade 
commercially available. 
Generation of chimeric mice (PXB-mice ) 
ch-Hepatocytes, BD195 (donor A, platable, inducible, and transporter activity qualified, 
2-year-old Hispanic girl), BD342 (donor B, platable, 2-year-old white girl), and BD85 (donor C, 
non-platable, 5-year-old African American girl) were purchased from BD Biosciences (Woburn, MA). 
cH-hepatocytes, IVT-JFC (donor D, platable, 1-year-old white boy) was purchased from BioIVT (Westbury, 
NY). These samples were obtained after written informed consent and this study was approved by 
Utilization of Human Tissue Ethical Committee of PhoenixBio Co., Ltd. (0028). ch-hepatocytes were 
thawed and transplanted into 2 to 4-week-old cDNA-uPA/SCID mice (PhoenixBio Co., Ltd., 
Higashihiroshima, Japan) via the spleen after butorphanol (Meiji Seika Pharma Co. Ltd., Tokyo, Japan) 
injection as previously described [14]. Three weeks after transplantation, 2 L of blood was collected 
periodically from the tail vein to measure human albumin (h-Alb) concentration. Blood h-Alb levels in 
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chimeric mice were measured by immunonephelometry in a model BM6050 autoanalyzer (JEOL, Tokyo, 
Japan) using LX Reagent Eiken Alb II (Eiken Chemical, Tokyo, Japan). All experimental animals reported 
in this article were housed with environmental enrichments under pathogen-free conditions and maintained 
in a 12-h light/dark cycle with sterilized ad libitum water and regular diet CRF-1 (Oriental Yeast, Tokyo, 
Japan). All experimental procedures were conducted in accordance with the guidelines provided by Proper 
Conduct of Animal Experiments (June 1, 2006; Science Council of Japan) and approved by the Animal 
Care and Use Committee of PhoenixBio Co., Ltd. (2287).  
Isolation and culture of cFHHs (PXB-cells ) 
To isolate cFHHs, 14 to 17-week-old chimeric mice with blood h-Alb levels >12 mg/mL 
(estimated replacement indexes >85% [donor A through C; Table 1]) were used. cFHHs were isolated from 
62 chimeric mice (9 mice for real-time quantitative reverse transcription polymerase chain reaction [qPCR] 
analysis, measurement of albumin secretion and CYP3A activity [Table 1], 6 mice for measurement of urea 
synthesis, 3 mice for CYP activity assay using a cocktail mixture of probe substrates, 6 mice for transporter 
immunohistochemistry and function assay, 24 mice for measurement of purity of h-hepatocytes, and 14 
mice for culture under several cell density conditions and microarray analysis) which were euthanized by 
exsanguination from the inferior vena cava under anesthesia using isofluorane (Mylan Pharmaceuticals Inc., 
Canonsburg, PA) in a two-step collagenase perfusion method as described below.  
The liver was perfused at 38ºC for 10 min at 1.5 mL/min with Ca2 -free and Mg2 -free Hanks' 
balanced salt solution (CMF-HBSS) containing 200 µg/mL ethylene glycol tetraacetic acid (EGTA), 1 
mg/mL glucose, 10 mM N-2 hydroxyethylpiperazine- -2- ethanesulfonic acid (HEPES), and 10 µg/mL 
gentamicin. The perfusion solution was then changed to CMF-HBSS containing 0.05% type IV collagenase 
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(Sigma-Aldrich Japan, Tokyo, Japan), 0.6 mg/mL CaCl2, 10 mM HEPES, and 10 µg/mL gentamicin, and 
perfusion was continued for 9 12 min at 1.5 mL/min. The liver was dissected and transferred to a dish; 
liver cells were gently disaggregated in the dish with CMF-HBSS containing 1% bovine serum Alb, 10 mM 
HEPES, and 10 µg/mL gentamicin. The disaggregated cells were centrifuged three times (50× g, 2 min). 
The pellet was suspended in medium consisting of Dulbecco's modified Eagle's medium (DMEM), 10% 
fetal bovine serum (FBS), 20 mM HEPES, 44 mM NaHCO3, and antibiotics (100 IU/mL penicillin G and 
100 µg/mL streptomycin). Cell number and viability were assessed using the trypan blue exclusion test.
For each assay, cFHHs isolated from a chimeric mouse or pooled cFHHs isolated from three or 
four chimeric mice were used. The cFHHs were inoculated in wells of type I collagen-coated 24-well or 
96-well plates at 0.53, 1.06, 1.60, or 2.13  105 cells/cm2, and cultured with dHCGM (DMEM containing 
10% FBS, 2% dimethylsulfoxide [DMSO], 20 mM HEPES, 44 mM NaHCO3, 15 g/mL L-proline, 0.25 
g/mL insulin, 5  10-8 M dexamethasone, 5 ng/mL epidermal growth factor, 0.1 mM L-ascorbic acid 
2-phosphate, 100 IU/mL penicillin G, and 100 µg/mL streptomycin) as we previously reported [25, 26]. 
The medium was replaced every 3 to 4 days. Portions of cells from day 0 samples were used for CYP3A 
activity measurements (in suspension) and total RNA isolation. ch-hepatocytes of donor A were thawed and 
cultured as cFHHs.   
Measurement of purity of h-hepatocytes in cFHHs 
Contamination by mouse cells in isolated cFHHs (donor A) was confirmed using 66Z rat IgG 
antibody specific for mouse cells [1]. The isolated cFHHs were incubated for 30 min with antibody 
conjugated to Dynabeads (Thermo Fisher Scientific, Waltham, MA) to recognize the surface of mouse cells, 
but not human cells. The ratio of bead-negative and -positive hepatocytes in the suspension of cFHHs was 
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determined by microscopy. The cFHHs were inoculated on type I collagen-coated wells of 24-well plates 
(2.13  105 cells/cm2) and cultured using dHCGM. The cells were fixed with 10% formaldehyde for 10 min 
and stained with 4 µg/mL Hoechst33258 (#S-23387; Sigma) for 10 min at 2, 13, 23, and 33 days at room 
temperature. The h-hepatocytes and m-cells were counted on the culture plates under a microscope. The 
h-hepatocytes were distinguished from mouse cells based on different patterns resulting from the Hoechst 
staining of the nuclei [27]. Two independent experiments were performed.  
Measurement of h-Alb concentration in culture supernatant and CYP3A activity 
cFHHs (donor A, B, C, Table 1) were inoculated in wells of type I collagen-coated 24-well plates 
(2.13  105 cells/cm2) and cultured with dHCGM for 21 days. Three wells were used for each condition. 
The culture supernatant was collected at 2, 7, 14, and 21 days, and h-Alb levels were measured by latex 
agglutination immunonephelometry as described above. Three independent experiments were performed 
using cFHHs isolated from three different mice (Table 1). The data are presented as mean ± SD. 
Sample preparation for evaluation of the CYP3A activities of cFHHs was conducted as 
previously reported [1]. The isolated (day 0) or cultured hepatocytes at 2, 7, 14, and 21 days were incubated 
in Krebs Henseleit buffer with 10 µM midazolam as substrate specific for the CYP3A subtype at 37°C for 
2 h. The incubated solution was collected, and the concentration of the 1'-hydroxymidazolam metabolite 
was measured by high-performance liquid chromatography (HPLC) using a Lachome Elite device (Hitachi 
High-Technology Co., Tokyo, Japan). HPLC was performed at a flow rate of 1.0 mL/min using an Xterra 
RP18 column (4.6  150 mm, 5 
quantification of 1'-hydroxymidazolam was 0.1 µmol/L. Three independent experiments using cFHHs 
isolated from three different mice were performed (Table 1). The data are presented as mean ± SD. 
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Measurement of mRNA expression levels by real-time qPCR
The cFHHs (donor A, B, C; Table 1) were inoculated in wells of type I collagen-coated 24-well 
plates (2.13  105 cells/cm2) and cultured with dHCGM for 2, 7, 14, and 21 days. The mRNA expression 
levels of human and mouse genes were quantified by qPCR. Total RNA was isolated from each hepatocyte 
sample of three wells at the defined times using TRIzol (In vitrogen Corporation, Carlsbad, CA) and treated 
with DNase (In vitrogen). cDNA was synthesized using 1 g of RNA, SuperScript III reverse transcriptase 
(In vitrogen), and random primers (In vitro bjected 
to qPCR. Genes were amplified with a set of gene-specific primers (S1 Table) and SYBR Green PCR mix 
(Applied Biosystems, Tokyo, Japan) using a 7500 Real-Time PCR System (Applied Biosystems). Cycling 
conditions were described previously [12]. Three independent experiments were performed using cFHHs 
isolated from three different mice (Table 1). The data are presented as mean ± SD. The species specificities 
of the human and mouse primers were confirmed using h- and m-hepatocyte cDNA, and non-specific 
amplification was not observed (data not shown). 
Immunostaining for MRP2 
The cFHHs (donor A) were inoculated in wells of type I collagen-coated 96-well plates (2.13 
105 cells/cm2) and cultured with dHCGM for 2, 7, and 14 days. For indirect immunofluorescence analysis, 
the primary antibody was anti-MRP2 antibody (GeneTex, Inc. Irvine, CA). cFHHs were fixed with 
formalin for 10 min and permeabilized with 0.25% Triton X-100 in 10 mM PBS (pH 7.5) for 10 min at 
room temperature. After incubation in PBS containing 10% donkey serum for 30 min, cells were incubated 
with primary antibodies and diluted in PBS overnight at 4°C. After washing with PBS containing Tween, 
cells were incubated with Alexa 488-conjugated anti-mouse IgG donkey serum as the secondary antibody 
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(Life Technologies Corporation, Carlsbad, CA) for 1 h at room temperature. Nuclei were stained with 
Hoechst 33258.  
Measurement of MRP2, sodium-taurocholate cotransporting polypeptide (NTCP), and BSEP 
activities 
The cFHHs (donor A, pooled cFHHs from three or four animals) were inoculated in wells of type I 
collagen-coated 24-well plates (2.13  105 cells/cm2) and cultured with dHCGM for 7 and 16 days (for the 
assay using CDFDA) or for 9 days (DBD). Sixteen days after plating, the cFHHs were incubated with 1.25 
washed twice followed by incubation with HBSS or Ca2+- and Mg2+-free HBSS. Cell morphology, bile 
canaliculi formation, and accumulation of 5-(and-6)-carboxy-2',7'-dichlorofluorescein (CDF) in bile 
canaliculi were analyzed with phase contrast and fluorescence microscopy (Bz-X, KEYENCE 
CORPORATION, Osaka, Japan), respectively. Seven days after plating, the cFHHs were preincubated in 
Ca2+- and Mg2+-
of CDF was observed using fluorescence microscope (KEYENCE CORPORATION). Two independent 
experiments using cFHHs isolated from two different mice were performed to ensure reproducibility. 
CsA at 37°C for 30 mi
incubated in HBSS at 37°C for 5 to 210 min. To inhibit substrate uptake by NTCP, cells were treated with 
CsA from the preincubation process onwards. To inhibit excretion of the substrate by the BSEP, cells were 
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treated with CsA with the DBD treatment during the washing process. The fluorescence of DBD that had 
accumulated in bile canaliculi was analyzed using fluorescence microscope (KEYENCE CORPORATION). 
Two independent experiments using cFHHs isolated from two different mice were performed to ensure 
reproducibility. 
Microarray analysis 
For microarray analysis, cFHHs (donor A, pooled cFHHs from 3-4 animals) were plated at high 
density (2.13  105 cells/cm2) or low density (0.53  105 cells/cm2) in wells of type I collagen-coated 
24-well plates and cultured for 7 days. Total RNA was isolated from pooled cells of three wells of each 
fresh and cultured cFHH at high density or low density. RNA extraction was conducted as described above. 
RNA integrity was assessed using a Bioanalyzer (Agilent Technologies, Santa Clara, CA). After total RNA 
was deemed to be of sufficient quality (A260/A280 >1.9 and 28S/18S ratios approaching 2), the samples 
were stored at -80 C until further analysis. Three individual experiments using cFHHs isolated from three 
different mice were performed and these RNA samples were used for microarray analysis. For this analysis, 
RNA samples were applied to the GeneChip® Human Genome U-133 Plus 2.0 Array (Affymetrix, Santa 
xpression 
array data were normalized using the MAS5 algorithm (Affymetrix). The signal reliability of each probe 
was determined based on the MAS5 Call algorithm (Affymetrix), and each probe was assigned to one of 
three flags (P: present, M: marginal, and A: absent). To correct for bias between chips, GeneChip CEL files 
were imported into GeneSpring14.8 (Agilent Technologies). Correlation analyses for the RMA-normalized 
logarithmic expression levels of all probe sets were performed using GeneSpring14.8. We deposited our 
array data to NCBI GEO (Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/) (accession no. 
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GSE153298).
Statistical analysis 
The data were analyzed with Statcel 4 (OMS Publishing Inc., Tokorozawa, Japan). 
Log10-transformed data obtained in qPCR analysis were used for statistical analysis. Results are expressed 
t-test 
when data were normally di t-test. Multiple-sample comparisons were 
made by one-way analysis of variance followed by post hoc analysis. Statistical significance was 
considered at p-values <0.05. 
Urea synthesis assay 
cFHHs (donor A) were cultured from day 1 in dHCGM. For the urea synthesis measurement at 
Scientific, Waltham, MA) instead of L-glutamine and removed FBS (GlutaMax medium). The culture 
medium at days 8 was collected and the concentration of urea was measured using QuantiChrom Urea 
Assay Kit (BioAssay systems, Hayward, CA). For the measurement at days 15, the medium was changed at 
days 13 and 14 in the GlutaMax medium. The culture medium at days 15 was collected and the 
concentration of urea was measured. 
Measurement of CYP activities using a cocktail mixture of probe substrates 
Sample preparation for the evaluation of the CYP1A2, CYP2C19, and CYP3A activities of 
cFHHs (Donor D) were conducted. The 
containing Primary Hepatocyte Maintenance Supplements (Thermo Fisher Scientific, Waltham, MA) with a 
probe substrate at 37°C for 2 h, namely 50 µM phenacetin, 50 µM S-mephenytoin, and 5 µM midazolam 
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for the assessment of the CYP1A2, CYP2C19, and CYP3A activities, respectively. The incubated solution 
-hydroxy S-mephenytoin, and 
1'-hydroxymidazolam) was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
LC-MS/MS analysis was performed on HPLC LC20A system (Shimadzu Corporation Kyoto, Japan) and 
Japan).  
Preparation of samples for mRNA expression analysis in fresh h-hepatocytes from human normal 
tissues
Fresh h-hepatocytes isolated at Hiroshima University Hospital were provided. Normal liver 
tissues were obtained from the resected liver of four patients (39- and 61-year-old men and 25- and 
57-year-old women) after written receiving consent prior to surgery, in accordance with the 1975 
Declaration of Helsinki. The hepatocytes were isolated via two-step collagenase perfusion and low-speed 
centrifugation [9]. They were then incubated in lysed in lysis buffer and stored in freezer until further use. 
Total RNA was isolated from each sample using RNeasy Micro Kit (Qiagen, Hilden, Germany). DNase 
treatment, cDNA synthesis, and qPCR analysis were conducted using the same procedure in the Materials 
and Methods. This study was approved by Utilization of Human Tissue Ethical Committee of PhoenixBio 
Co., Ltd. (0051).
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Results
Morphology of cFHHs and contamination of mouse cells in cFHHs
To verify the lot-to-lot variations, cFHHs were isolated from chimeric mice transplanted with 
cells from the three different donors and cultured at high density. Animal information, yield, and viability 
of the cFHHs from each chimeric mouse are summarized in Table 1. At least 108 cells were collected from 
each chimeric mouse. Regardless of the original characteristics of ch-hepatocytes (donor A and B: platable, 
donor C: non-platable) before transplantation into host mice, all cFHHs were highly platable. The cultured 
cFHHs showed matured hepatocyte morphology for at least 3 weeks and many bile canaliculi had formed 
between cells at 7 days (Fig 1A and S3 Fig.). There were no clear differences in cFHH morphologies 
among the donors (Fig 1A).  
To analyze the presence of contaminating mouse cells, freshly isolated cFHHs were treated with 
66Z-conjugated magnetic beads. In this culture condition, hepatocytes do not proliferate. Microscopic 
observation revealed that the average ratio of h-hepatocytes to total cells in the freshly isolated cFHHs was 
90.3  2.9% (22 animals). We also counted the number of h-hepatocytes and contaminating mouse cells at 
2, 13, 23, and 33 days after plating. Two days after plating, the cultured cell density (h-hepatocytes and 
mouse cells) was approximately 1.5 × 105 cells/cm2. At day 13, cell density decreased to approximately 
80% of the day 2 density, and then remained stable for at least 33 days. The m-hepatocytes decreased in 
this condition, and the ratio of h-hepatocytes to total cells was 93% at 2 days, and then gradually increased 
to 98% at 33 days (Fig 1B). These results suggested that the present culture conditions were more suitable 
for h-hepatocytes than for mouse cells.  
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The expression profiles of mouse cyp (m-cyp) 1a2 and 3a11 mRNAs were analyzed by qPCR 
using mouse-specific primer sets. Expression of both m-cyp mRNAs drastically decreased and the lowest 
level was <1% (cyp1a2) and 0.1% (cyp3a11) of basal expression level (day 0) at 7 days (Fig 1C). 
Evaluation of h-Alb secretion, urea synthesis, CYP activities, and CYP, UGT, and transporter mRNA 
expressions in cFHHs 
All cFHHs showed similar h-Alb secretion ability at 2 days (approximately 0.7 g/105 cells/day) 
and 7 days (approximately 1.4 g/105 cells/day). After day 7, the secretion of albumin was maintained until 
day 21 (Donor A and C) or gradually reduced to day 2 levels (Donor B) (Fig 2A). 
The synthesis of urea by cFHHs (donor A) was measured at days 8 and 15. Stable urea synthesis 
6 cells/day) and 15 (1.42 mM/day, 
6 cells/day). These data were similar to those in the previous report (0.42 mM/day, 
6 cells/day) [28].  
The CYP3A activity of cFHHs was measured using midazolam as a substrate (Fig 2B). The 
activities in suspension (day 0) were different among the donors, but all activities decreased at 2 days and 
then recovered to or increased over basal levels after 7 days. The CYP3A activity in donor A was lower 
than in those in donors B and C. The recovered activity levels were maintained during the culture period. 
According to the mouse hepatocyte contamination rate and m-cyp3a11 mRNA expression levels (Fig 1B 
and 1C), CYP3A activities in cFHHs might be derived from human hepatocytes. 
Expression patterns of several human hepatic genes were analyzed by qPCR using cultured 
cFHHs from three donors (Fig 2C-2O). Two genes, CYP1A2 and UGT2B7, showed donor differences in 
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these expression levels at day 0. In the case of cFHHs, the expression level of CYP1A2 in donor B was 10
times lower than in donors A or C (Fig 2D). The expression level of UGT2B7 in donor A was also 10 times 
lower than those in donors B and C in the case of cFHHs (Fig 2K). Except for CYP1A2 and UGT2B7, the 
other hepatic genes showed similar basal expression levels at day 0. Through the culture period, the 
h-hepatocytes from the three donors showed similar expression profiles. Two expression patterns were 
evident during culture. In the first pattern, expression levels decreased at day 2 and then remained stable 
between 2% and 120% of the initial levels (day 0, isolated hepatocytes; CYP1A1, CYP1A2, CYP2B6, 
CYP2C9, CYP2D6, CYP2E1, UGT2B7, BSEP, organic anion transporting polypeptide [OATP] 1B1, and 
OATP1B3). In the second pattern, expression levels decreased at 2 days, but increased to higher than the 
initial levels, which were maintained until 21 days (CYP3A4, UGT1A1, and MRP2). The expression 
pattern of CYP3A4 mRNA was very similar to CYP3A activity (Fig 2B and 2I). Although CYP3A 
activities of donor A was a little lower than those of donor B and C, mRNA expressions of CYP3A4 were 
similar among the three donors. The mRNA expression levels of 10 of 13 CYP and UGT enzymes and 
transporters were maintained at >10% of the levels of freshly isolated cFHHs after 21 days. Those of 
hUGT2B7 (7.1%), hBSEP (2.3%), and hOATP1B1 (7.7%) were decreased by <10% of the initial levels 
(Table 2).  
Expression levels of the genes in PXB-cells cultured for 2, 7, 14, and 21 days were compared to 
those in freshly isolated PXB-cells (day 0). The results represent mean (ratio (%) of the day 0 level)  SD of 
three independent experiments. 
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Comparison of Characteristics between cFHHs and ch-hepatocytes from same donor or fresh adult 
h-hepatocytes.  
The ch-hepatocytes from donor A were specified by the provider as platable hepatocytes with 
CYP induction and transporter abilities. The ch-hepatocytes were thawed and cultured in the same 
conditions as cFHHs for 14 days to compare their morphologies, h-Alb secretion, and CYP and UGT 
mRNA expression levels. In the present culture conditions, the ch-hepatocytes also maintained matured 
hepatocyte morphology. The results of h-Alb quantification indicated that there was no significant 
difference in the h-Alb production abilities of the cultured ch-hepatocytes and the cFHHs after at least 14 
days (S1 Fig.). qPCR analysis revealed that there was a difference of over two log in the CYP3A4 mRNA 
expression levels between the ch-hepatocytes and cFHHs at day 0. However, after day 2, the CYP3A4 
mRNA expression levels in the cultured ch-hepatocytes were comparable or slightly lower than those in the 
cultured cFHHs at the same time points. The mRNA expression patterns of the CYPs and UGTs were 
similar to those in cFHHs (S1 Fig.). The ch-hepatocytes of donor C did not attach to the dishes as observed 
in donor A.  
The cryopreserved hepatocytes used for transplantation in chimeric mice were derived from very 
young donors (2-5 years old). To confirm the phenotype of hepatic expression in the chimeric mouse liver, 
we compared hepatic gene expression (CYPs and UGTs) in cFHHs (from donor A, B, and C) and fresh 
h-hepatocytes from 4 adult donors (25-, 39-, 57-, and 61-year-old). The expression levels of CYP1A2 and 
UGT1A1 among the measured 6 genes (CYP1A2, CYP2C9, CYP2D6, CYP3A4, UGT1A1, and UGT2B7) 
in cFHHs were similar to those in h-hepatocytes from adult donors. Although the expression levels of 
- 88 - 
CYP2D6 and CYP3A4 were higher and those of UGT2B7 were lower in fresh h-hepatocytes than in 
cFHHs, there were no statistical differences between them (S2 Fig.).  
Localization and function of MRP2, NTCP, and BSEP in cFHHs
Localization of the efflux transporter MRP2 in the cFHHs of donor A was confirmed by 
immunocytochemistry. There were no obvious signals in the cFHHs at day 0 and 2 (Fig 3A). However, 
MRP2 was localized to bile canalicular membranes at 7 days and the positive spots were enlarged at 14 
days (Fig 3A). To analyze the transporter activity of MRP2, the cultured cFHHs (donor A) were treated 
with CDFDA at 16 days. Sustained accumulation of CDF, a fluorescent metabolite of CDFDA, was 
observed in the bile canaliculi in the presence of Ca2+ (S3 Fig). On the other hand, the CDF signals rapidly 
disappeared from the bile canaliculi in the absence of Ca2+. This observation indicated that in the presence 
of Ca2+ the integrity of the bile canalicular networks remains intact, while in the absence of Ca2+ the 
integrity of the canalicular space is disrupted, causing leakage of the canalicular contents, as reported 
previously [29]. Treatment with the potent MRP2 inhibitor CsA at 10 and 100 M significantly inhibited 
the accumulation of CDF in the bile canaliculi, and intense fluorescence signals were observed in the 
cytoplasm (Fig 3B). To analyze the transporter activity of NTCP and BSEP, the cultured cFHHs (donor A) 
were treated with DBD at 9 days. DBD was incorporated into the cFHHs and accumulated in bile canaliculi 
(Fig 3C). To inhibit uptake of the substrate by NTCP, cells were treated with CsA from the preincubation 
process onwards, before treatment with DBD at 37 . To inhibit excretion of the substrate by BSEP, cells 
were treated with CsA from the washing process onwards, following DBD treatment at 37 . Treatment 
with CsA before or after DBD addition decreased the accumulation of DBD in the bile canaliculi (Fig 3C 
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and D). cFHHs retained MRP2 and BSEP activities, although mRNA expression level of BSEP were 2% to 
3% at 7, 14, and 21 days compared with day 0 (Table 2). 
Effects of cell density on morphologies and liver-specific functions of the cultured cFHHs
We predicted that the high density culture might induce the maintenance of high gene expression 
levels of phase I and II enzymes and transporters. To test this hypothesis, cFHHs were inoculated on type I 
collagen-coated plates at densities of 0.53, 1.06, 1.60, and 2.13  105 cells/cm2. The freshly isolated cFHHs 
were highly platable, and firmly attached to type I collagen-coated plates 15 to 30 min after plating. Seven 
days after plating, cells inoculated at 0.53 and 1.06 105 cells/cm2 were pre-confluent, and cells and nuclei 
were flattened at these plating densities (Fig 4A). When hepatocytes were plated at 1.60 and 2.13  105
cells/cm2, they became confluent. Cells cultured at 2.13  105 cells/cm2 were densely packed and bile 
canalicular structures were clearly observed between hepatocytes. However, cells plated at 1.60  105
cells/cm2 were somewhat flat and bile canalicular structures were fewer than those between cells plated at 
2.13  105 cells/cm2 (Fig 4A). Microscopic observation revealed that approximately 60% to 73% of cells 
were attached to the plate surface in the various density conditions at 7 days (Table 3). To evaluate the 
effect of cell density on hepatocyte functions, h-Alb levels in the culture media were examined at 7 days. 
The h-Alb levels per 105 attached cells at 7 days are shown in Fig 4B. Compared with those cultured at 
lower cell densities, cFHHs cultured at higher densities displayed significantly higher albumin secretion 
(Fig 4B). The qPCR results clearly indicated that the mRNA expression levels of CYP1A1, CYP1A2, 
CYP2B6, CYP3A4, MRP2, OATP 1B1, and BSEP decreased in the PXB-cells cultured at the lowest 
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density, although the difference in MRP2 expression was not statistically significant (Fig. 4C). However, 
UGT1A1 expression was stable at all examined densities 
From these results, gene expression profiles of isolated cFHHs and cultured cFHHs from donor A 
at high density (2.13  105 cells/cm2) or low density (0.53  105 cells/cm2) were compared by microarray 
analysis. The gene expression profile of cFHHs cultured at 7 days at high density was close to that of 
isolated cFHHs (correlation efficiency: 0.911). In contrast, correlation efficiency between isolated cFHHs 
and cFHHs cultured at low density at 7 days was very low (0.736).  
The mRNA expression profiles of cFHHs cultured at high density and low density were 
compared. Gene profiles were compiled using microarrays representing 54675 human transcripts. Among 
these, 22893 transcripts (42% of total probes) were assigned as present (P flag) for all cFHHs at either high 
density or low density. Moreover, of those 22893 transcripts, 1247 (5.4%) were expressed at levels two-fold 
lower in the cFHHs at low density than at high density (p<0.05, two-  t-test).  
Pathway analysis was then performed on the 1247 transcripts down-regulated in cFHHs at low 
density on day 7. As a result, 32 pathways were detected (p>0.001 minimum number of matches > 10), of 
which five were nuclear receptor (NR)-related pathways (Table 4). The 1247 transcripts down-regulated in 
low density cultured cFHHs included seven transcription factors (TFs), 27 phase I metabolic enzymes, 11 
phase II metabolic enzymes, and 53 transporters. Down-regulated TF, phase I and II enzymes, and 
transporter genes are shown in S2 Table. 
mRNA expression of HNF4  and other TFs in cFHHs
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In NR-related pathways detected by pathway analysis, the gene expression levels of significantly 
down-regulated TFs including NRs (HNF4 , CAR, and PXR) and an unchanged NR (FXR) were 
determined from the cFHHs of three donors (Table 1) cultured for 21 days. The mRNA expression of 
HNF4 , PXR, and FXR were quantified using qPCR. Levels were maintained at day 0 levels for at least 21 
days. In contrast, CAR expression decreased to approximately 10% at day 2 and this level was maintained 
for 21 days (Fig 5). From these results, we concluded that CYP and UGT genes and transporter genes 
might be regulated by the expression of these TFs in high density cultured cFHHs. 
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Discussion
It is recognized that ch-hepatocytes are the gold standard for in vitro studies of DMPK and 
toxicology [30-33]. However, the use of ch-hepatocytes is limited by lot size (at most several hundred vials 
from one donor), and there are individual differences among donors. Because of these limitations, 
researchers have been using immortalized liver-derived cell lines, such as HepG2, HepaRG, and induced 
pluripotent stem cell-derived hepatocytes for their in vitro studies [34]. Although some liver-specific 
functions are confirmed in these cells, many other liver functions were still significantly lower than those in 
primary h-hepatocytes [34-36] 
In the case of humanized-liver mice, the transplanted ch-hepatocytes dramatically proliferate 
more than 1000-fold in the host mouse liver. Therefore, more than 108 hepatocytes can be isolated from a 
chimeric mouse. Our previous results revealed that most genes showed comparable expression levels in the 
human hepatocytes of both human and chimeric mouse livers [12]. The humanized-liver mouse has been 
used in many studies of DMPK, safety, and hepatitis B virus and hepatitis C virus infections. These facts 
indicate that chimeric mice transplanted with ch-hepatocytes derived from one donor could stably and 
repeatedly supply a large amount of fresh h-hepatocytes.  
In general, h-hepatocytes undergo changes in cell morphology and rapidly lose their hepatic 
functions, such as CYP expression and albumin secretion, in tradittional 2D culture model [37, 38]. To 
overcome this problem, several different types of culture methods have been established [6, 39]. In this 
study, we developed a novel culture system in which human hepatocytes maintain high hepatic function for 
at least 21 days. In this culture system, cFHHs isolated from PXB-mice were plated on type I 
collagen-coated plates at high density (2.13 × 105 cells/cm2) in the dHCGM medium we previously 
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developed [25]. h-Alb secretion, CYP3A activity, and mRNA expression levels were compared among 
three types of cFHHs isolated from three PXB-mice transplanted using different donors. Individual 
differences between mice were small in all data tested. There were no significant differences between the 
hepatic function of donors, except for CYP3A activity and the mRNA expressions of hCYP1A2 and 
hUGT2B7.  
We previously compared the activities of cFHHs and the corresponding cryopreserved 
ch-hepatocytes [1]. As a result, the CYP1A2, 2C19, 2D6, and 3A activities in cFHHs were more than twice 
those in the cryopreserved ch-hepatocytes. We also compared the activities in cFHHs and cryopreserved 
cFHHs by a programmed freezer. Freezing decreased the CYP1A2 and 2D6 activities significantly. The 
decreased metabolism in cryopreserved hepatocytes may be attributable to two mechanisms: inactivation of 
P450 enzymes and loss of the cofactor NADPH due to cell membrane damage [40]. In addition, the CYP 
activities of cFHHs and thawed ch-
of CYP1A2 using phenacetin in cFHHs and thawed ch-hepatocytes was 75.9  1.8 and 3.9 pmol/106
cells/min, respectively. The activity of CYP2C19 using S-mephenytoin in cFHHs and thawed 
ch-hepatocytes was 35.5  0.9 and 3.1 pmol/106 cells/min, respectively. The activity of CYP3A using 
midazolam in cFHHs and thawed ch-hepatocytes was 18.4  1.2 and 5.0 pmol/106 cells/min, respectively. 
These results of the CYP activities of cFHHs were similar or higher than those in ch-hepatocytes. We 
measured the major CYPs and UGTs mRNA expression levels in the ch-hepatocytes of donor A, resulting 
in extremely low levels (1/5-1/1000 compared to cFHHs), most likely due to the degradation of RNAs as a 
result of freeze and thaw. Interestingly, after 2 days, the mRNA expression levels of ch-hepatocytes 
recovered to levels of cFHHs (S1 Fig). 
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Several previous studies have reported that cultured cell density could affect hepatocyte-specific 
functions in h-hepatocytes [41], rat hepatocytes [42], and HepaRG [43]. Regardless of the culture models 
and hepatocyte sources, the cell density of cultured hepatocytes might be one of the most essential factors 
for the maintenance of liver-specific functions in vitro. We predicted that the high density culture of cFHHs 
should generate long-term high liver function levels. To test this hypothesis, cFHHs were cultured at both 
high density and low density, and the gene expression levels were compared using microarray analysis. The 
mRNA expressions of 1247 genes, including phase I and II metabolic enzymes and transporter genes, were 
significantly up-regulated in the high density culture conditions compared to low density conditions. NR 
pathways were significantly overrepresented following pathway analysis of the 1247 genes. The mRNA 
-regulated in high density culture. The mRNA expression 
of  were maintained at similar levels to the 
freshly isolated cFHHs, while the level of CAR mRNA decreased to approximately 10% of the level in 
freshly isolated cFHHs.  
HNF4  and the CAR, PXR, and FXR control hepatic genes including CYP, UGT, and 
transporters. CYP2B6, 2C9, 2D6, and 3A4 are regulated by HNF4  [44-52]. The expression of CYP2B6 
and CYP2C9 mRNA are also affected by CAR and PXR [53-55]. Although, the expression of PXR and 
HNF4 in cultured cFHHs were maintained at day 0 levels for 21 days, a CAR expression decreased to 
approximately 10% of day 0 level during the culture period. We suggest that the decreased expressions of 
CYP2B6 and CYP2C9 in cultured cFHHs might be due to decreased CAR expression. OATP1B1 is 
regulated by PXR, FXR, and CAR [56-59], suggesting that its gene expression in cultured cFHHs might be 
affected by the decrease in CAR expression.  
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CAR may also regulate expressions of CYP3A4, MRP2, and UGT1A1 [60-65]. However, their 
gene expressions were maintained in cFHHs in the present study, suggesting that other regulatory 
CYP1A1 and UGT1A1 are affected by AhR. It was reported that C/EPBa and VDR affect CYP2D6 and 
MRP2, respectively. These data highlight the need for further explorations of the changes in the expression 
of these genes. 
In this study, we provide the first evidence that the mRNA expressions of HNF4 , PXR, and 
FXR are maintained in high density culture conditions. These results suggest that the expression levels of 
some TFs might affect the maintenance of hepatic genes, such as CYP UGT, and transporters of cFHHs in 
high density culture conditions. Better understanding of the cross-talk mechanisms of TFs and their target 
genes, such as CYPs and UGTs, and transporters in vitro and in vivo by optimization of culture conditions 
are important. Further experiments involving siRNAs or gene transfer-mediated overexpression of these 
TFs into cFHHs are needed. 
In this paper, we mainly measured the mRNA expression levels of metabolic enzymes, and the 
CYP3A activity, albumin secretion, and urea synthesis were determined during culture. Recently, we 
published the CYP activities of cFHHs of donor A after 21 days in the same culture condition [66]. CYP 
mRNA expression in the present study was compared with the corresponding activities in this paper during 
culture. The mRNA expression levels and the activities of CYP1A2 and CYP2D6 were decreased at day 7 
and remained at similarly low levels until day 21. On the other hand, the CYP2C9 mRNA decreased 
gradually and reached 0.3 at day 21 compared to that at day 0; however, the activity was around 1.0 during 
culture. The CYP3A4 mRNA levels increased gradually and reached 4.0 at day 21 compared to that at day 
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0; however, the activity of CYP3A was around 1.0 during culture. Thus, the relation of the mRNA 
expression levels and activities were different among CYPs.  
We already compared the CYP activities of cFHHs derived from young donors and adult PHHs 
(54-, 57-, and 75-year-old) in our previous paper [1]. The resulting CYP activities were similar between the 
cFHHS from young donors and adult PHHs. We have newly determined the level of mRNA CYP 
expression between cFHHs from young donors and adult PHHs , resulting there were no statistical 
differences between them (S2 Fig.) 
A disadvantage to the use of humanized-liver mice as a source of h-hepatocytes is contamination 
by mouse parenchymal and non-parenchymal cells. In this study, h-hepatocytes isolated from chimeric 
mice showed a high replacement index (>90%). In a previous study, we demonstrated that contamination 
with m-hepatocytes did not show any effects on the results of a drug metabolizing assay using cFHHs in 
suspension cultures [1]. In this study, we investigated the viability of the mouse cells and several 
liver-specific gene expressions of m-hepatocytes in the culture conditions. The ratio of mouse cells to total 
cultured cells was approximately 6% to 7% at 2 days after seeding and decreased to 2% to 3% at 32 days. 
In addition, m-cyp1a2 and cyp3a11 mRNAs drastically and quickly decreased to 0.1% to 1% of the basal 
expression levels during the culture period. These results suggest that the m-cyps, at least cyp1a2 and 3a11, 
only marginally, if at all, affect the results of the metabolic study using the present in vitro model. 
We compared the hepatic functions of cFHHs and original ch-hepatocytes in the present culture 
conditions. The original ch-hepatocytes (donor A) are commercially as Transporter-Qualified Plateable 
Cryopreserved Human Hepatocytes. The original hepatocytes also attached on collagen-coated plates at 
high cell densities, as did the cFHHs, and the expression levels of CYP3A4 mRNA in the original 
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ch-hepatocytes were comparable or lower than those in the cFHHs at 7 days and 14 days. On the other hand, 
the original ch-hepatocytes derived from donor C showed poor platability, and it was impossible for them 
to attach in the culture conditions even at high density (data not shown). These results suggest that, 
regardless of the characteristics of the original ch-hepatocytes, the liver-specific functions of cFHHs were 
comparable or higher than those of ch-hepatocytes classified as the highest grade.  
Here, we demonstrated that cFHHs cultured at a high density could stably maintain several 
hepatic functions for long periods, using a conventional culture method with collagen-coated plates. In 
conclusion, cFHHs are a valuable tool for in vitro metabolic and pharmaco-toxicological studies. 
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Tables and figures 
Table 1. Data of isolated hepatocytes for evaluation of drug metabolizing enzymes (phase I and II) and transporters gene expression 













A-1 male 15 18.79 17.2 2.24 × 108 91.7 
A-2 male 15 17.42 16.4 1.69 × 108 92.6 
A-3 male 15 19.06 17.1 1.52 × 108 83.9 
B 
BD342 
B-1 male 16 17.45 12.6 1.31 × 108 87.5 
B-2 male 16 17.54 15.2 1.53 × 108 93.8 
B-3 male 17 17.19 12.6 1.42 × 108 87.3 
C 
BD85 
C-1 female 14 15.3 13.0 1.42 × 108 89.5 
C-2 male 15 14.4 14.0 1.27 × 108 86.7 
C-3 male 15 20.6 14.3 1.04 × 108 79.5 
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Table 2. Relative gene expression levels of human drug metabolizing enzymes (phase I and II) and transporters 
 Days in culture 
 2 7 14 21 
Phase I enzymes 
hCYP1A1 2.4 ± 1.2 12.2 ± 5.5 25.9 ± 8.2 38.9 ± 7.0 
hCYP1A2 6.3 ± 7.6 9.0 ± 14.1 20.7 ± 33.1 21.0 ± 32.8 
hCYP2B6 29.7 ± 21.5 40.3 ± 16.9 25.1 ± 9.2 31.1 ± 11.0 
hCYP2C9 16.6 ± 8.2 25.0 ± 14.3 15.6 ± 9.8 23.8 ± 10.0 
hCYP2E1 9.7 ± 5.2 8.4 ± 4.1 21.4 ± 17.1 23.2 ± 12.1 
hCYP2D6 13.0 ± 5.2 8.8 ± 6.7 8.2 ± 5.1 11.8 ± 4.9 
hCYP3A4 7.8 ± 2.5 127.8 ± 70.6 178.7 ± 122.1 238.3 ± 155.1 
Phase II enzymes 
hUGT1A1 52.4 ± 17.9 269.2 ± 143.2 214.2 ± 105.4 292.9 ± 118.2 
hUGT2B7 26.3 ± 8.4 9.4 ± 7.2 6.1 ± 3.7 7.1 ± 2.1 
Transporters 
hBSEP 5.7 ± 2.5 3.0 ± 1.2 2.1 ± 1.0 2.3 ± 0.7 
hMRP2 53.5 ± 22.0 167.4 ± 72.5 206.1 ± 125.3 256.8 ± 114.8 
hOATP1B1 3.9 ± 1.8 2.9 ± 1.3 5.9 ± 2.3 7.7 ± 1.3 
hOATP1B3 4.5 ± 1.6 12.6 ± 4.8 13.3 ± 4.9 14.7 ± 0.3 
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Table 3. Attached cell number and ratio of the number of attached cells to seeded cell number
Seeding cell number 
(× 105 cells/cm2) 
Attached cell number on day 
7 
(× 105 cells/cm2) 
Cell adhesion ratio on day 7 
(%) 
2.13 1.27 ± 0.22 59.75 ± 10.27 
1.60 1.00 ± 0.18 62.36 ± 11.30 
1.06 0.74 ± 0.08 69.42 ± 7.91 
0.53 0.39 ± 0.02 72.51 ± 3.53 
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Table 4. Top 20 pathways in descending order in pathway analysis (p>0.001 Minimal number of matches>10) on day 7   
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Fig 1. Morphology, viability, and purity of cFHHs during culture. 
A: Phase contrast microphotographs of cFHHs during culture at day 7, 14 and 21. cFHHs 
isolated from chimeric mice transplanted with three different donor cells (Donor A, B, and C) 
were plated at 2.13 x 105 cells/cm2 and cultured. The inserts are high magnification images. 
Scale bars denote 100 µm in the low magnification images and 50 µm in the high 
magnification images. B: Cell numbers and ratio of h-hepatocytes during culture. cFHHs 
isolated from two different chimeric mice transplanted with donor A cells were plated 
(2.13 105 cells/cm2) and fixed at days 2, 13, 23, and 33. After Hoechst staining, h-hepatocytes 
and mouse cells were counted by microscopic observation of three to five fields. Total cell 
numbers and percentages of h-hepatocytes are denoted by dotted and normal lines, 
respectively. C: Mouse gene expression levels during culture. Expression levels of m-cyp1a2 
and 3a11 mRNA were measured by qPCR on days 0, 2, 7, 14, and 21. Data are expressed as 
mean ± SD. *p<0.05 versus at day 2; **p<0.01 versus at day 2; #p<0.05 versus at day 12; 
##p<0.01 versus at day 12. 
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Fig 2. Hepatic function and gene expression in cFHHs during culture. 
A: h-Alb production, B: CYP3A activities, C-O: Human gene expression levels (C: CYP1A1, D: CYP1A2, 
E: CYP2B6, F: CYP2C9, G: CYP2D6, H: CYP2E1, I: CYP3A4, J: UGT1A1, K: UGT2B7, L: BSEP, M: 
MRP2, N: OATP1B1, O: OATP1B3). cFHHs collected from chimeric mice transplanted with cells of three 
different donors (A, B, and C) were plated at 2.13 105 cells/cm2 and cultured for up to 21 days. Results 
represent means  SD of three independent experiments. The Y-axis of C to O represents the relative 
expression level of each gene to that in freshly isolated cFHHs originating from donor A. Day 0 shows the 
values of isolated cFHHs. 
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Fig 3. Expression and function of transporters in cFHHs during culture. 
A: Transporter protein localization and activity in cultured cFHHs. cFHHs (donor A) were plated at 2.13 
105 cells/cm2. cFHHs were cultured for 7 and 14 days and fixed, and MRP2 protein expression was 
determined by immunostaining. Images of cFHHs after double staining with MRP2 (green) and Hoechst 
(blue) are presented. Scale bar denotes 100 m. B: MRP2 transporter activity was determined in cultured 
cFHHs using CDFDA. cFHHs were incubated with CDFDA and CsA (10 or 100 M) at day 7. CsA 
treatment inhibited the accumulation of CDF in the bile canaliculi, and intense fluorescence signals were 
observed in the cytoplasm at 10 and 100 M CsA. Scale bar denotes 100 m. C: NTCP and BSEP 
transporter activities were determined in cultured cFHHs using DBD and CsA. DBD was incorporated into 
cFHHs and accumulated in bile canaliculi between cFHHs at day 9, as shown in green. To inhibit uptake of 
the substrate by NTCP, cells were treated with CsA from the preincubation process onwards, before DBD 
treatment. To inhibit excretion of the substrate by BSEP, cells were treated with CsA from the washing 
process onwards, after DBD treatment. Scale bar denotes 100 m. Effect of CsA treatment on DBD-uptake 
in cells via NTCP, and DBD-excretion in bile canaliculi via BSEP. D: Photographs of microscopy images 
were taken at 210 min and areas of DBD accumulation in bile canaliculi were measured using a Bz-X 
analyzer. DBD that had accumulated in bile canaliculi was expressed as a ratio with the control (CsA [-]). 
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Fig 4. cFHHs cultured at different cell densities. 
A: Phase contrast microphotographs of cFHHs plated at 0.53, 1.06, 1.60, and 2.13 105 cells/cm2 and 
cultured for 7 days. Arrows show bile canalicular structures. Scale bar denotes 100 m. B: h-Alb levels in 
culture supernatant of cFHHs cultured at different cell densities. These results represent the mean  SD of 
three independent experiments. **p<0.01 C: Gene expression levels of human phase I and II enzymes in 
cFHHs plated at 0.53, 1.06, 1.60, and 2.13 × 105 cells/cm2 and cultured for 7 days. Each gene expression 
level was measured by qPCR. These results represent the mean ± SD of three independent experiments. *p 
< 0.05, **p < 0.01 
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Fig 5. Human TF gene expression levels in cultured cFHHs. 
A: B: hCAR, C: hPXR, D: hFXR. cFHHs from three different donors were plated at 2.13  105
cells/cm2 and cultured for up to 21 days. The gene expression levels were measured by qPCR. Results 
indicate the mean  SD of three independent experiments. The y-axis represents the relative expression 
level of each gene to the level in freshly isolated cFHHs originating from donor A. Day 0 shows the mRNA 
levels of isolated cFHHs. 
- 119 - 
Supporting information 
S1 Table. Primer sets
Gene name F-primer R-primer 
hCYP1A1 TCAACCATGACCAGAAGCTA AAGATAATCACCTTCTCACTTAACAC 
hCYP1A2 GCTTCTACATCCCCAAGAAAT ACCACTTGGCCAGGACT 
hCYP2B6 ACCCAACACACCAGCTTCCG CAGGATTGAAGGCGTCTGGTTTTTC 
hCYP2C9 CCAGATCTGCAATAATTTTTCTC CAAGCTTTCAATAGTAAATTCAGATG 
hCYP2D6 CTTGGACAAAGCCGTGA GACAGCATTCAGCACCTC 
hCYP2E1 GGCTGAAGTAAAAGAGTATGTGTC TTTCCTTCTCCATTTCCAC 
hCYP3A4 ACTGCCTTTTTTGGGAAATA GGCTGTTGACCATCATAAAAG 
hUGT1A1 TTGATCCCAGTGGATGGC ATGCTCCGTCTCTGATGTACAAC 
hUGT2B7 TGACATGAAGAAGTGGGATCAG CAACATTTGGTAAGAGTGGATATGG 
hOATP1B1 TCATACTCTGTGAAAACAAATCAG CAGACTGGTTCCCATTGAC 
hOATP1B3 CTCTGTTTGCTAAAATGTACGTG GAAGAAATAATGGAAAATAGTCCAG 
hBSEP AAATATGCTTTTGGGTCATTG GTCAGCTATGGCATCATTG 
hMRP2 TCCAACTGTGCTTCAAGC GGCATCCACAGACATCAG 
hHNF4  GACCGCCAGTATGACTCG CGTTGGTTCCCATATGTTCC 
hCAR ATTGAAGATGGAGCCCG GAGCTGCAGTTTTCGTAGTG 
hPXR AGCTACTCCTTGATCGATCC AAAGTCAGCATGGTTCCAG 
hFXR ATGGATTCATATAACAAACAGAGG GCTTTTTTGTGAATTCTACAAGAAC 
hGAPDH GGAGTCAACGGATTTGGT AAGATGGTGATGGGATTTCCA 
mCyp1a2 CTCCTTTAAGGAAAACCCAACCACC ACAACACTGGGTCAGAATCTCATTG 
mCyp3a11 CTAAGCAGAAGCACCGAGTGG TTTCTGGATATCAGGGTGAGTGG 
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S2 Table. Altered expression of genes after 7 days at high density compared to 7 days at low density. 
Fold change 
Transcription factors Phase I enzymes Phase II enzymes Transporters 
NR Others CYP FMO UGT SULT GST NAT ABC SLC 
2-4 1H3 (LXRa),  
1I2 (PXR),  
3C2 (AR),  
5A2 (LRH-1) 
HNF4A 2C18, 2J2,  
3A4, 3A43 
3 1A6,3A1 1A1 A4 A8, C2 (MRP2),  
C3 (MRP3),  
C6 (MRP6)/C6P1/C6P2, G2 
2A2 (GLUT2), 7A2 (CAT2),  
15A1 (PEPT1), 16A10 (MCT10), 
19A3 (THTR2), 22A18, 22A25, 23A1, 
25A13 (AGC2),  
25A15 (ORC1), 25A20 (CAC), 25A3, 
25A33, 25A42, 30A10, 31A1, 35D1, 
44A1 (CTL1),  
46A3, 50A1 47A1 (MATE1) 
4-6 0B2 (SHP1) 2W1, 4F3, 4F12,  
8B1, 39A1 
2A3 2A1  8 C6P1, G5 13A5 (NACT), 17A3 (NPT4),  
22A3 (OCT3), 38A4 (ATA3)
>6 1I3 (CAR) 2A6, 2A7, 2B6,  
2C8, 2C9, 2C19,  
2D6/2D7, 2E1, 3A7, 






A6, B4 (MDR3),  
G8 (GBD4) 
6A1 (GAT-1), 10A1 (NTCP), 17A4, 1A2 
(GLT1),  
22A1 (OCT1), 22A7 (OAT2), 25A47, 
28A1 (CNT1), 38A3, 39A5, 51A (OST 
alpha),  
O1B1 (OATP1B1),  
O1B3 (OATP1B3)
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S1 Fig. h-Alb levels and gene expression levels of human phase I and II enzymes in cultured 
PXB-cells and original ch-hepatocytes (donor A) 
PXB-cells originating from donor A and original ch-hepatocytes (donor A) were plated at 2.13  105
cells/cm2 and cultured for up to 14 days. h-Alb levels in the culture supernatant were measured using 
ELISA. *p < 0.05; **p < 0.01 (two- -test). Each gene expression level was measured by 
qPCR. The results represent single determination (day 0; n = 1) or the mean  S.D. of triplicate 
determinations in separate wells of the culture plate (day 2, 7, and 14; n = 3) from a single experiment. The 
y-axis represents the relative expression level of each gene to that of the original ch-hepatocytes. Day 0 
denotes the mRNA levels of isolated PXB-cells or thawed ch-hepatocytes. *p < 0.05; **p < 0.01 
(two- -test). 
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S2 Fig. Gene expression levels of human phase I and II enzymes in cFHHs and fresh adult 
h-hepatocytes (unplated) 
cFHHs were collected from chimeric mice transplanted with cells of donor A, B, and C. Fresh adult 
h-hepatocytes were collected from excess normal liver tissues of surgical liver resections from 4 donors. 
Each gene expression level was measured by qPCR. The results indicate the relative value to the average 
of cFHHs normalized by value of hGAPDH. The results of cFHHs indicate the mean  S.D. of three 
different animals. The results of fresh adult h-hepatocytes indicate the mean  S.D. of four donors from 25 
to 61 years of age. The y-axis represents the relative expression level of each gene to the mean value of 
cFHHs.
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S3 Fig. MRP2 transporter activity in cFHHs. 
At day 16, cFHHs were incubated with HBSS containing 1.25 M CDFDA for 5 min, and then incubated 
for up to 30 min in the presence or absence of Ca2+. CDF accumulation in bile canaliculi between cFHHs 
was observed as green spots. The bar denotes 100 m. 
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IV. General conclusion 
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h-Hepatocytes are considered to be useful as a source of cells for drug development. It is recognized 
that ch-hepatocytes are the gold standard for in vitro studies of DMPK and toxicology [1-4]. However, the 
use of ch-hepatocytes is limited by lot size (at most several hundred vials from one donor), and there are 
individual differences among donors. Because of these limitations, researchers have been using 
immortalized liver-derived cell lines, such as HepG2, HepaRG, and induced pluripotent stem cell-derived 
hepatocytes for their in vitro studies [5]. Although some liver-specific functions are confirmed in these 
cells, many other liver functions were still significantly lower than those in primary h-hepatocytes [5-7]. 
This study aimed to propagate h-hepatocytes to obtain functional h-hepatocytes for drug development.  
In Chapter II, I made primary cultures of h-hepatocytes in the presence of Swiss 3T3 cells and 
demonstrated the presence of CF-PHs. The occupancy rate of CF-PHs was~0.1%. I devised a method to 
propagate CF-PHs by serial sub-culturing and characterized the propagated CF-PHs. Human CF-PHs were 
able to be subcultured within limited passages. CF-PHs from young donors (3-month- to 12-year-old) 
could be passaged 7 times, Population doubling time (PDT) at passage 4 being170-220 h, and, then the 
cells became senescent. CF-PHs from older donors (63- to 72-year-old) were passaged only 5 times at most. 
They grew more slowly, their PDT at passage 4 being 650-1200 h. These results suggested that replication 
potential of h-CF-PHs is correlated with the age of donors. It should be emphasized that the cumulative 
population doubling level (CPDL) of CF-PHs from younger donors, 3-month-old and 12-months-old, were 
as high as 19.3 and 24.7 during 300 days, respectively. CF-PHs showed a liver epithelial cell-like 
morphology when they were in the growth phase and in an early phase of confluence, whereas they 
showed a typical hepatocyte-like morphology in condensed regions at confluence. I examined whether 
human CF-PHs in spheroid culture elevate differentiation-related genes. The mRNA expression level of 
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albumin (ALB), hepatocyte-nuclear factor 4 (HNF4 ), and CYPs of CF-PHs were low in 
monolayer-culture. However, when these CF-PHs were cultured in spheroid, they regained the expression 
of mRNAs of ALB and HNF4  to a level comparable to that of the original h-hepatocytes, i.e., the cells 
before cultivation, and also regained a mRNA expression profile of CYPs of 2C9, 2C19, and 3A4 similar 
to that of original h-hepatocytes. Currently, I suppose that h-CF-PHs cultured in spheroids reexpress 
hepatocyte specific differentiation markers through the up-regulation of HNF4  expression. This study 
demonstrated the presence of CF-PHs, a highly replicative compartment of h-hepatocytes, even in the adult 
human liver. These CF-PHs can be serially subcultured, retaining their normal hepatocytic characteristics.  
These cultures should be useful to study the cellular and molecular mechanisms of growth, 
differentiation, toxicity, metabolism, and carcinogenesis of human hepatocytes. However, I considered that 
it is difficult to obtain large number of differentiated h-hepatocytes using this method, because ratio of 
CF-PHs was very low (~0.1%) in h-hepatocytes. 
We succeeded in propagating human hepatocytes in mouse livers by transplanting h-hepatocytes into 
uPA/SCID or cDNA-uPA/SCID mice via spleen. The mouse liver was replaced with h-hepatocytes at more 
than 70%[8, 9] . We call the mice, PXB-mice. Our previous results revealed that most genes showed 
comparable expression levels in the h-hepatocytes of both human and PXB-mouse livers [10]. The 
PXB-mouse has been used in many studies of DMPK, safety, and HBV and hepatitis C virus infections. In 
the case of PXB-mice, the transplanted ch-hepatocytes dramatically proliferate more than 1000-fold in the 
host mouse liver. Therefore, more than 108 hepatocytes can be isolated from a PXB-mouse (PXB-cells).  
These facts indicate that PXB-mice transplanted with ch-hepatocytes derived from one donor could 
stably and repeatedly supply a large amount of fresh h-hepatocytes. 
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In Chapter III and IV, it was determined whether the PXB-mouse could be a useful source of fresh 
h-hepatocytes for in vitro drug development tests.  
In Chapter III, I compared the CYP and UGT activities of ch-hepatocytes and PXB-cells. Compared 
with ch-hepatocytes, the CYP (1A2, 2C9, 2C19, 2D6, 2E1, 3A) activities of PXB-cells were similar or 
greater. Moreover, ketoprofen was more actively metabolized through glucuronide conjugates by 
PXB-cells than by ch-hepatocytes. I concluded that fresh and reproducible PXB-cells could be a useful tool 
in predicting the pharmacokinetics of chemical entities.  
In general, h-hepatocytes undergo changes in cell morphology and rapidly lose their hepatic functions, 
such as CYP expression and ALB secretion, in traditional 2D culture model [11, 12]. To overcome this 
problem, several different types of culture methods have been established [13, 14]. In Chapter IV, I 
developed a novel culture system in which PXB-cells maintain high hepatic function for at least 21 days. 
In this culture system, PXB-cells were plated on type I collagen-coated plates at high density (2.13 × 105
cells/cm2) in the dHCGM medium we previously developed [15]. h-ALB secretion, CYP3A activity, and 
mRNA expression levels were compared among three types of PXB-cells isolated from three PXB-mice 
transplanted using different donors. PXB-cells cultured at high density displayed stable production of 
h-ALB and CYP3A activities for at least 21 days. The mRNA expression levels of 10 of 13 CYP, UGT, and 
transporters were maintained at >10% of the levels of freshly isolated PXB-cells after 21 days. From 1 
week, many bile canaliculi were observed between PXB-cells, and the accumulation of the MRP and BSEP 
in these bile canaliculi was clearly inhibited by cyclosporin A.  
Several previous studies have reported that cultured cell density could affect hepatocyte-specific 
functions in h-hepatocytes [16], rat hepatocytes [17], and HepaRG [18]. Regardless of the culture models 
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and hepatocyte sources, the cell density of cultured hepatocytes might be one of the most essential factors 
for the maintenance of liver-specific functions in vitro. I predicted that the high density culture of 
PXB-cells should generate long-term high liver function levels. To test this hypothesis, PXB-cells were 
cultured at both high density and low density, and the gene expression levels were compared using 
microarray analysis. The mRNA expressions of 1247 genes, including phase I and II metabolic enzymes 
and transporter genes, were significantly up-regulated in the high density culture conditions compared to 
low density conditions. Nuclear receptor (NR) pathways were significantly overrepresented following 
LRH-1, SHP1 and CAR), which are up streams of several CYP, UGT and transporter genes, were 
up- , PXR, and FXR in high density 
culture at 21 days were maintained at similar levels to the freshly isolated PXB-cells, while the level of 
CAR mRNA decreased to approximately 10% of the level in freshly isolated PXB-cells. I demonstrated 
that PXB-cells cultured at a high density could stably maintain several hepatic functions for long periods, 
using a conventional culture method with collagen-coated plates.  
These results suggested PXB-cells are a valuable tool for in vitro drug development studies including 
metabolic and pharmaco-toxicological studies. 
Previously, the in vitro culture method using induced pluripotent stem cells (iPSCs) was developed for 
obtaining large number of differentiated human hepatocytes [19]. This method using iPSCs requires a step 
for propagating undifferentiated cells and several steps for differentiation of the undifferentiated cells into 
hepatocytes by gene transfer or culturing them in the specified culture medium. In addition, the functions 
of hepatocytes obtained from iPSCs were not sufficient compared with mature human hepatocytes. On the 
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other hand, spheroid culture of CF-PHs and PXB-cells have high hepatic functions similar to mature 
human hepatocytes in vitro. 
It was concluded that the present studies clarified the important culture conditions for supplying large 
number of functional human hepatocytes for research of drug discovery. 
- 130 - 
References
1) Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: 
current understanding of the regulation of metabolic enzymes and transporter proteins, and 
pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, 
clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39(1):159-234. Epub 2007/03/17. doi: 
10.1080/03602530601093489. PubMed PMID: 17364884. 
2) Soars MG, McGinnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. 
Chem Biol Interact. 2007;168(1):2-15. Epub 2007/01/09. doi: 10.1016/j.cbi.2006.11.002. PubMed 
PMID: 17208208. 
3) Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT. In vitro evaluation of potential 
hepatotoxicity induced by drugs. Curr Pharm Des. 2010;16(17):1963-77. Epub 2010/03/20. doi: 
10.2174/138161210791208910. PubMed PMID: 20236064. 
4) Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 
2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and 
non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell 
signaling and ADME. Arch Toxicol. 2013;87(8):1315-530. Epub 2013/08/27. doi: 
10.1007/s00204-013-1078-5. PubMed PMID: 23974980; PubMed Central PMCID: 
PMCPMC3753504. 
5) Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line 
Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31(8):1035-42. 
Epub 2003/07/18. doi: 10.1124/dmd.31.8.1035. PubMed PMID: 12867492. 
- 131 - 
6) Sauer V, Roy-Chowdhury N, Guha C, Roy-Chowdhury J. Induced pluripotent stem cells as a source 
of hepatocytes. Curr Pathobiol Rep. 2014;2(1):11-20. doi: 10.1007/s40139-013-0039-2. PubMed 
PMID: 25650171; PubMed Central PMCID: PMCPMC4312414. 
7) Nishimura M, Ueda N, Naito S. Effects of dimethyl sulfoxide on the gene induction of cytochrome 
P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of 
human hepatocytes. Biol Pharm Bull. 2003;26(7):1052-6. Epub 2003/07/05. doi: 
10.1248/bpb.26.1052. PubMed PMID: 12843640. 
8) Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized 
liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004;165(3):901-12. 
Epub 2004/08/28. doi: 10.1016/s0002- 52 9440(10)63352-4. PubMed PMID: 15331414; PubMed 
Central PMCID: PMCPmc1618591 
9) Tateno C, Kawase Y, Tobita Y. Hamamura S, Ohshita H, Yokomichi H, et al. Generation of novel 
chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One. 
2015;10(11): e0142145. doi: 10.1371/journal.pone.0142145. PubMed PMID: 26536627. 
10) Tateno C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, et al. Morphological and microarray 
analyses of human hepatocytes from xenogeneic host livers. Lab Invest. 2013;93(1):54-71. Epub 
2012/11/14. doi: 10.1038/labinvest.2012.158. PubMed PMID: 23147226. 
11) Nishimura M, Ueda N, Naito S. Effects of dimethyl sulfoxide on the gene induction of cytochrome 
P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of 
human hepatocytes. Biol Pharm Bull. 2003;26(7):1052-6. Epub 2003/07/05. doi: 
10.1248/bpb.26.1052. PubMed PMID: 12843640. 
- 132 - 
12) Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicol 
Res (Camb). 2013;2(1):23-39. doi: 10.1039/C2TX20051A. PubMed PMID: 23495363; PubMed 
Central PMCID: PMCPMC3593300. 
13) Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. Meeting the challenge of predicting hepatic 
clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, 
HepatoPac. Drug Metab Dispos. 2013;41(12):2024-32. doi: 10.1124/dmd.113.053397. PubMed 
PMID: 23959596. 
14) Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, et al. Characterization of primary 
human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and 
disease. Sci Rep. 2016;6:25187. doi: 10.1038/srep25187. PubMed PMID: 27143246; PubMed Central 
PMCID: PMCPMC4855186. 
15) Ishida Y, Yamasaki C, Yanagi A, Yoshizane Y, Fujikawa K, Watashi K, et al. Novel robust in vitro
hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J 
Pathol. 2015;185(5):1275-85. doi: 10.1016/j.ajpath.2015.01.028. PubMed PMID: 25791527. 
16) Greuet J, Pichard L, Ourlin JC, Bonfils C, Domergue J, Le Treut P, et al. Effect of cell density and 
epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human 
hepatocytes in primary culture. Hepatology (Baltimore, Md). 1997;25(5):1166-75. Epub 1997/05/01. 
doi: 10.1002/hep.510250520. PubMed PMID: 9141435. 
17) Nakazawa K, Shinmura Y, Yoshiura Y, Sakai Y. Effect of cell spot sizes on micropatterned cultures of 
rat hepatocytes. Biochem Eng J. 2010;53(1):85-91. doi: 10.1016/j.bej.2010.09.013. 
- 133 - 
18) Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional expression of 
sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG 
cell line. Eur J Pharm Sci. 2006;28(1-2):109-17. Epub 2006/02/21. doi: 10.1016/j.ejps.2006.01.004. 
PubMed PMID: 16488578. 
19) Takayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., Nonaka, A., 
Sakurai, F., Hayakawa, T. and Mizuguchi, H. (2012). Efficient generation of functional hepatocytes 
from human embryonic stem cells and induced pluripotent st
Molecular Therapy, 20(1), 127-137. 
